

## **Distribution Agreement**

In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.

---

Anish Sanjay Shah, MD

---

Date

## **Approval Sheet**

Stress Reactivity  
Disturbances of the Neurocardiac Axis

By

Anish Sanjay Shah, MD  
Master of Science  
Clinical Research

---

Amit J. Shah, MD, MSCR  
Advisor

---

Matthew Magee, MPH, PhD  
Committee Member

---

Alvaro Alonso, MD, PHD  
Reader

Accepted:

---

Lisa A. Tedesco, PhD  
Dean of the James T. Laney School of Graduate Studies

---

Date

Stress Reactivity  
Disturbances of the Neurocardiac Axis

By

Anish Sanjay Shah  
M.D., Texas A&M University, 2016  
B.S. Emory University, 2011

Advisor:

Amit J. Shah, MD, MSCR

An abstract of  
A thesis submitted to the Faculty of the  
James T. Laney School of Graduate Studies of Emory University  
in partial fulfillment of the requirements for the degree of  
Master of Science in Clinical Research  
2021

## Abstract

### Stress Reactivity Disturbances of the Neurocardiac Axis

By

Anish Sanjay Shah, MD

Stress, both physiological and psychological, serve as triggers for cardiovascular events in those with a damaged cardiac substrate, such as ischemic heart disease. The physiological reaction to stress is mediated through the autonomic nervous system, which can be quantified through heart rate variability (HRV).

We measured HRV in three cohorts that had varying burdens of ischemic heart disease, from no known disease, high risk of disease, and known disease after myocardial infarction. Each cohort also had varying types of HRV, from short-term recordings during acute psychological and physiological stress, to longer, diurnal recordings. Two of these cohorts were followed longitudinally to assess for cardiovascular outcomes and mortality. Short-term and cosinor HRV metrics served as the exposure and psychological stress, myocardial ischemia, and major adverse cardiovascular events (MACE) served as outcomes in logistic regression modeling and survival analysis.

Autonomic dysfunction was robustly associated with psychological stress, myocardial ischemia, and MACE. We found a significant relationship between circadian autonomic variability and depression and posttraumatic stress disorder. We found that autonomic dysfunction was also strongly related to mental stress-induced myocardial ischemia. We found that autonomic dysfunction, both to circadian changes and acute mental stress, was associated with an increased, independent risk for MACE.

This suggests that autonomic dysfunction, measured by HRV, plays an important, independent role in the additional cardiovascular risk seen in patients with psychological disease. This association highlights neurocardiac mechanisms as a not yet understood pathological process in both psychiatric and cardiovascular disease that may have implications in diagnosis and therapy.

Stress Reactivity  
Disturbances of the Neurocardiac Axis

By

Anish Sanjay Shah  
M.D., Texas A&M University, 2016  
B.S. Emory University, 2011

Advisor:

Amit J. Shah, MD, MSCR

A thesis submitted to the Faculty of the  
James T. Laney School of Graduate Studies of Emory University  
in partial fulfillment of the requirements for the degree of  
Master of Science in Clinical Research

2021

Stress Reactivity  
Disturbances of the Neurocardiac Axis

Anish Sanjay Shah

A thesis submitted for the degree of  
*Master of Science in Clinical Research*

Laney Graduate School

Emory University

2021-04-02

# Contents

<b>Acknowledgements</b>	<b>v</b>
<b>Abbreviations</b>	<b>vi</b>
<b>INTRODUCTION</b>	<b>2</b>
1 The Problem	2
2 The Approach	4
<b>BACKGROUND</b>	<b>6</b>
3 Clinical Importance	6
4 Relevant Literature	8
<b>METHODS</b>	<b>11</b>
5 Specific Aims	11
6 Study Design	13
6.1 Population Characteristics and Study Overview . . . . .	13
6.1.1 Emory Cardiovascular Biobank ( <i>Biobank</i> ) . . . . .	13
6.1.2 Emory Twins Study ( <i>Twins</i> ) . . . . .	13
6.1.3 Mental Stress Ischemia Mechanisms and Prognosis, Myocardial Infarction and Mental Stress ( <i>MIMS/MIPS</i> ) . . . . .	14
6.2 Measurements . . . . .	15
6.2.1 Electrocardiography Measures . . . . .	15
6.2.2 Psychological Measures . . . . .	16
6.2.3 Cardiac Measures . . . . .	17
6.3 Sample Size and Power Considerations . . . . .	18
7 Analysis	20
7.1 Myocardial Ischemia . . . . .	20
7.2 Psychological Stress . . . . .	21
7.3 Clinical Outcomes . . . . .	22
<b>RESULTS</b>	<b>25</b>
8 Study Overview	25

<i>CONTENTS</i>	iii
<b>9 Psychological Stress</b>	<b>26</b>
<b>10 Myocardial Ischemia</b>	<b>28</b>
<b>11 Clinical Outcomes</b>	<b>30</b>
<b>DISCUSSION</b>	<b>32</b>
<b>12 Principal Findings</b>	<b>32</b>
12.1 Psychological Stress . . . . .	32
12.2 Myocardial Ischemia . . . . .	34
12.3 Clinical Outcomes . . . . .	37
<b>13 Limitations and Future Direction</b>	<b>39</b>
<b>CONCLUSIONS</b>	<b>43</b>
<b>REFERENCES</b>	<b>45</b>
<b>APPENDIX</b>	<b>56</b>
<b>A TABLES AND FIGURES</b>	<b>56</b>
A.1 Clinical Overview . . . . .	56
A.1.1 Overview of Stress Reactivity . . . . .	57
A.1.2 Biobank Cohort Description . . . . .	58
A.1.3 Twin Cohorts Description . . . . .	59
A.1.4 Mental Stress Cohorts Description . . . . .	60
A.1.5 HRV in Twins Cohorts . . . . .	61
A.2 Psychological Stress . . . . .	62
A.2.1 HRV and Mental Stress Challenge . . . . .	63
A.2.2 Distribution of HRV and Mental Stress Challenge . . . . .	64
A.2.3 Depression and PTSD with Mental Stress Challenge . . . . .	65
A.2.4 Depression by PHQ-9 and HRV . . . . .	66
A.2.5 HRV and Chronic Mental Stress in Twins . . . . .	67
A.2.6 Circadian Autonomic Variability and Chronic Mental Stress . . . . .	68
A.3 Myocardial Ischemia . . . . .	69
A.3.1 Relationship Between Obstructive and Non-Obstructive Coronary Artery Disease . . . . .	70
A.3.2 Effective of Revascularization on Autonomic Function . . . . .	71
A.3.3 HRV by Timing of Revascularization . . . . .	72
A.3.4 Relationship of HRV with both Mental and Physical Stress . . . . .	73
A.3.5 Quantitative Myocardial Perfusion and HRV . . . . .	74
A.3.6 Circadian HRV and Myocardial Perfusion . . . . .	75
A.3.7 Distribution of HRV and MSIMI . . . . .	76
A.3.8 Modeling Mental Stress-Induced Myocardial Ischemia and HRV . . . . .	77



A.4	Clinical Outcomes . . . . .	78
A.4.1	Outcomes in Twins . . . . .	79
A.4.2	Circadian Outcomes in Twins . . . . .	80
A.4.3	Outcomes in MIMS/MIPS . . . . .	81
<b>B</b>	<b>Supplementary Files</b>	<b>82</b>
B.0.1	Poincaré Plot of HRV . . . . .	83
B.0.2	Cosinor Metrics . . . . .	84

## Acknowledgements

Foremost, I would like to thank my mentors and mentoring team. Dr. Shah has been a tremendous supporter of my academic growth, and has challenged me to continue to explore and learn, and create an area of academic excellence for myself. Dr. Alonso and Dr. Thames have all supported my efforts through direct mentorship and academic guidance. Dr. Quyyumi and Dr. Vaccarino have created a research environment that has laid the groundwork for these projects.

Second, I would like to thank the support staff that has allowed this research to unfold, from the EPICORE group with Nancy Murrah and Lucy Shallenberger, to the MSCR program with Cheryl Sroka and the outstanding MSCR instructors, including Dr. Matthew Magee.

Finally, I would like to thank my family for their support, including Michelle for her patience, and to Ripley and Harper for the always welcome distractions.

# Abbreviations

Term	Abbreviation
ANS	Autonomic Nervous System
Biobank	Emory Cardiovascular Biobank
CAD	Coronary Artery Disease
CFR	Coronary Flow Reserve
CVD	Cardiovascular Disease
HRV	Heart Rate Variability
IHD	Ischemic Heart Disease
MACE	Major Adverse Cardiovascular Events
MI	Myocardial Infarction
MIMS	Myocardial Infarction and Mental Stress
MIPS	Mental Stress Ischemia Prognosis Study
MPI	Myocardial Perfusion Imaging
MSIMI	Mental Stress-Induced Myocardial Ischemia
PSIMI	Physical Stress-Induced Myocardial Ischemia
PTSD	Post-Traumatic Stress Disorder
Twins	Emory Twins Study

# INTRODUCTION

# 1 The Problem

“Why did he die on Tuesday and not on Monday?”

— Douglas Zipes

The underlying premise in this question posed by Dr. Zipes is that the cardiac substrate can be *triggered* into a catastrophic event (1). That trigger is oftentimes psychological in nature, and in the right setting, such as a scarred myocardium, can lead to electrical instability and ventricular arrhythmias (2). The two critical components in understanding these critical events is thus contributions of the cardiac substrate to overall risk and the propensity for triggers to lead to events. Thus, understanding how cardiovascular disease and neuropsychological triggers contribute and compete in the pathogenesis of major adverse cardiovascular events (MACE) is critical.

Patients with psychiatric disease have an increased of cardiovascular disease and overall mortality (3,4). Depression, for example, is the leading cause of disability in the world (5), and coronary artery disease (CAD) is the leading cause of death (6). The prevalence of depression is 20% in patients with CAD, and in those with comorbid depression and CAD, there is a 3-fold increase in cardiovascular mortality (7,8). This demonstrates that both psychological and cardiac disorders contribute to the risk for increased mortality through additional, not yet defined, mechanisms. This additional risk is likely represented by both the underlying amount of cardiovascular disease and how the body reacts to psychological stress, leading to a triggering event.

The purpose of this thesis is to examine the mechanism by which psychological stress interacts with ischemic heart disease (IHD), and subsequently leads to an increased risk for cardiovascular events. This shared pathway is likely through disturbances of the neurocardiac axis, and requires a method to measure stress and stress reactivity

upon the system to help quantify the additional risk (9). By leveraging different types of physiological stress along varying levels of ischemic burden, we can understand the additional risk of neurocardiac disease.

## 2 The Approach

The suspected mechanism behind the pathogenesis of neurocardiac disease is through dysfunction of the autonomic nervous system (ANS), which has been shown to have an increased risk of mortality (10,11). Both psychological stress and myocardial ischemia are known to have a relationship with ANS dysfunction (12), and the interaction between sympathetic and parasympathetic nervous activity likely mediates the additional cardiovascular risk. By using clinical cohorts with varying cardiac substrates, such as increasing burden of IHD, and varying types of triggers, from acute mental stress, chronic psychological stress, and circadian changes, we can assess the competing, additional risk of autonomic dysfunction.

To measure ANS dysfunction, a common surrogate is through electrocardiographic (ECG) changes based on sympathetic and vagal effects upon the sinoatrial node, or pacemaker, of the heart. The corresponding heart rate variability (HRV), and its mathematical derivatives, can thus inform us of the dynamic changes to autonomic tone (13). By measuring autonomic changes during different stressors, we can quantify stress reactivity and subsequently examine its relationship with both psychological stress and ischemic burden, and measure the additional risk for MACE.

# BACKGROUND



### 3 Clinical Importance

Psychological stress is increasingly recognized as an important potentially modifiable risk factor for cardiovascular disease (14). Psychiatric disease leads to an increase cardiovascular disease and overall mortality. PTSD, for example, has twice the hazard ratio for not only progressive coronary artery disease, but also for overall mortality (4). Depression and loneliness have a distinct increase in all-cause mortality (15), and almost twice twice the risk of coronary artery disease (16). Specifically, depression is the leading cause of disability worldwide, estimated to be prevalent in over 300 million people, which accounts for roughly 4% of the global population (5). In the United States, the estimated economic burden of depression is \$210 billion dollars as of 2010, doubling in cost from 2000 (17), suggesting a worsening, growing burden. CAD on the other hand remains the leading cause of death (6). This corresponds with approximately \$204 billion dollars of estimated direct and indirect costs, with both continuing to climb (18).

In individuals with CAD, the prevalence of depression is estimated to be 20%, and in those with comorbid depression and CAD, there is over a 3-fold increase in cardiovascular mortality (7,8). This increased risk of mortality in CAD with depression has remained unchanged over the past 35 years (19), as only in recent years has depression been considered an additional prognostic marker of mortality in CAD (20).

Although interventions such as cognitive behavioral therapy and antidepressants are well-proven in reducing symptoms of psychological distress, their impacts are only modest in patients with CAD, and they do not impact event-free survival (21). Although the American College of Cardiology recommends depression should be routinely screened for in patients with cardiovascular disease, there is limited evidence that this leads to an improvement in overall mortality (22). More research

is needed to understand the therapeutic mechanism underlying psychological distress and CAD (19), as there are no effective therapies for these high-risk individuals in comorbid patients.

The causal mechanism is suspected to be through ANS dysfunction, as this has been found to occur in both diseases of the brain and heart (9). Not only are somatic symptoms of psychological stress predictive of cardiovascular mortality, but they may be explained by changes seen in HRV (23,24). Similarly, abnormalities in myocardial perfusion are related to and may be predated by abnormalities in HRV (26). Thus, investigating the role of autonomic dysfunction in neurocardiac disorders is both mechanistically plausible and may allow for the development of efficacious therapeutic interventions.

## 4 Relevant Literature

The heart itself harbors an intrinsic cardiac nervous system that responds to changes in autonomic tone, such as in myocardial ischemia and infarction, by changing chronotropic, inotropic, and dromotropic responses (27,28). Autonomic dysfunction occurs at multiple levels, from central neurological processes to cardiovascular reflexes (29). This includes vagal withdrawal seen in depression and heightened sympathetic tone seen in PTSD or cardiovascular disease. Depression, for example, has been linked to dysregulation of the ANS through changes in levels of catecholamines (30), increased cardiovascular reactivity to stress (31), and decreased baroreflex sensitivity (32).

ANS-related mechanisms are important as they are related to both cardiac and neuropsychological disorders. The autonomic innervation of the heart has been shown repeatedly to play a critical role in myocardial ischemia (33–35). Historically, stellectomy was found to reduce angina pectoris and ventricular dysrhythmias (36). Modern interventions have shown to improve symptom burden not only in CAD, but also in depression (37). Vagal nerve stimulation has been shown to relieve cardiac arrhythmias, and has been effective against treatment-resistant depression (38). In PTSD, non-invasive vagal nerve stimulation has also been found to blunt the sympathetic response to stress (39). These relationships between chronic psychological stress, cardiac perfusion and arrhythmias, and the ANS help to establish the important influences on the neurocardiac axis.

HRV has been shown to be an effective ECG-based biomarker for ANS dysfunction. HRV is an accepted measure of autonomic activity, as it is an integration of sympathetic and parasympathetic efferent input at the level of the sinoatrial node (40). For example, the non-linear HRV marker of *Dyx* has been shown to predict ventricular dysrhythmia and cardiovascular mortality after myocardial infarction,

with a hazard ratio of 2.4 (95% CI 1.5 – 3.8) (41). In addition, individuals with chest pain and abnormal *Dyx* had an odds ratio of 8 (95% CI 3.1 – 23.99) for abnormal exercise stress test (42). Not only does HRV correlate well with cardiovascular disease, but is strongly correlated with depression (11). This relationship between psychological stress, cardiovascular disease, and the autonomic nervous system is thus an appropriate candidate for further investigation, particularly in justifying the clinical utility in measuring autonomic dysfunction (12). In addition to chronic mental stress, acute mental stress has become a more common way of assessing physiological reactivity. Mental stress has been shown to associate with chronic psychological stressors (43), and can also lead to the development of myocardial ischemia (44). This phenomenon, known as mental stress-induced myocardial ischemia (MSIMI), is an important reaction to stress that has been shown to predict long-term clinical outcomes (45). HRV has been shown that to associate with acute mental stress (46), but the relationship between MSIMI has not yet been determined.

The circadian rhythm in autonomic dysfunction is also relevant. The response to the stress of changing from sleep to wake has been seen to associate with increased cardiovascular mortality. There is an increased frequency of sudden cardiac death based on time of day, usually peaking between 6 AM and 10 AM (47,48), with a secondary peak between 6 PM and 8 PM (49). There is a circadian pattern to autonomic outflow, melatonin, cortisol, and circulating catecholamines which could increase vulnerability to ischemia and cardiac death during morning hours [(48); Scheer2010]. The relationship of circadian changes in HRV and myocardial perfusion has been shown to be related (26), but how circadian changes may be important in psychological stress and overall mortality is not yet known. Thus, studying circadian autonomic variability may reveal insights into the diurnal nature of clinical disease.

# **METHODS**

## 5 Specific Aims

The response to both physiological and psychological stress can be markers of overall cardiovascular adaptability. The following aims help to assess the clinical importance of stress reactivity as measured by disturbances to the neurocardiac axis at different levels of cardiovascular risk.

### **AIM I — Autonomic mechanisms underlying psychological stress.**

1. Examine the effect of acute mental stress on sympathovagal balance and cardiac autonomic function in a cohort of participants with CAD undergoing a laboratory based mental stress challenge. *We hypothesize that heart rate is higher and HRV is lower during both stress and recovery phases of acute mental stress challenge as compared to the rest phase.*
2. Examine the relationship of cardiac autonomic dysfunction measured in the setting of acute mental stress challenge with depression and posttraumatic stress disorder in a cohort of participants with CAD undergoing a laboratory based mental stress challenge. *We hypothesize that lower short-term HRV during acute stress associate with depression and PTSD.*
3. Examine the relationship of circadian cardiac autonomic variability over 24 hours with depression and PTSD in a cohort of male veteran twins. *We hypothesize that lower circadian variation in HRV (amplitude) and 24-hour mean HRV (mesor) associate with depression and PTSD.*

### **AIM II — Autonomic mechanisms underlying ischemic heart disease.**

1. Examine the relationship of baseline resting cardiac autonomic dysfunction with obstructive coronary artery disease (>70% stenosis) in a cohort of high-risk patients undergoing coronary angiography. *We hypothesize that short-term autonomic metrics are lower in subjects with obstructive, epicardial disease*

*compared to those without evidence of obstructive CAD.*

2. Examine the acute effect of revascularization of obstructive coronary artery disease on short-term cardiac autonomic function compared to changes that otherwise occur by angiography alone, without intervention. *We hypothesize that in subjects undergoing revascularization of the coronary arteries, short-term HRV is lower after revascularization as compared to before revascularization and also compared to HRV during angiography.*
3. Examine the relationship of early morning and circadian autonomic variability with conventional myocardial ischemia and flow reserve in a cohort of male veteran twins. *We hypothesize that lower early morning HRV and circadian HRV variability associate with greater conventional myocardial ischemia and lower myocardial flow reserve.*
4. Examine the relationship between acute changes in cardiac autonomic function during mental stress challenge and mental stress induced myocardial ischemia in a cohort of participants with stable CAD. *We hypothesize that mental stress-induced decreases in HRV associate with an increased odds of mental stress-induced myocardial ischemia.*

**AIM III — Autonomic mechanisms underlying the risk of major adverse cardiovascular events.**

1. Examine the relationship of early morning and circadian autonomic variability with CVD and all-cause mortality in a cohort of male veteran twins. *We hypothesize that lower early morning HRV and circadian HRV variability associate with an increased hazard for overall and cardiovascular mortality.*
2. Examine the relationship between acute changes in cardiac autonomic function during mental stress challenge and future major adverse cardiovascular events in a cohort of participants with stable CAD. *We hypothesize that mental stress-induced decreases in HRV associate with an increased hazard for cardiovascular mortality and recurrent cardiovascular events.*

## 6 Study Design

### 6.1 Population Characteristics and Study Overview

#### 6.1.1 Emory Cardiovascular Biobank (*Biobank*)

The *Biobank* studies major cardiovascular events, and also evaluates additional biomarkers for inflammation, cardiac injury, and genetics, with the goal of identifying novel factors associated with the pathobiological process and treatment of CVD (50). All patients aged 18 years and older undergoing cardiac catheterization were included. During the index cardiac catheterization, additional measures including lifestyle factors, psychological status, medical comorbidities, revascularization and previous procedures were ascertained via patient interview and chart review. Additionally, ambulatory ECG was collected with the VivaLNK patch, which was placed on the morning of cardiac catheterization and removed after catheterization for up to 24 hour of data recording. Patients were excluded if they have congenital heart disease, severe valvular heart disease, severe anemia, a recent blood transfusion, myocarditis, history of active inflammatory disease, cancer or are unable or not willing to provide consent (approximately 5%). Those that are found to have atrial fibrillation or have >20% ectopic beat burden or noise, as well as those that are pacemaker dependent were excluded. Those with known CAD were also excluded.

#### 6.1.2 Emory Twins Study (*Twins*)

The *Twins* is a longitudinal cohort study designed to examine the relationship of depression and PTSD with myocardial perfusion abnormalities, with follow-up focused on CVD outcomes and changes in perfusion over time. In addition, the study design allows for studying the relationship between myocardial perfusion with autonomic function, measured hourly over the course of 24 h, in individuals without



known ischemic heart disease. Subjects were drawn from the Emory Twin Study, which recruited middle-aged male twin pairs from the Vietnam Era Twin Registry (51–53). Pairs of twins were examined at the Emory University General Clinical Research Center, and all data collection occurred during a 24-hour admission under controlled conditions. The twins in each pair maintained a nearly identical schedule, with all data collection beginning and ending at the same time. The twins arrived at 11 AM, with ECG recording started at approximately 1 PM, questionnaires and exam performed between 2 and 4 PM, dinner at 5 PM, bedtime at 10 PM, wake-up time at 6:30 AM, and PET scans performed between 8 and 10 AM the following morning. The twins were followed longitudinally for follow-up events, including review of national registries, which were adjudicated. Subjects were excluded from analysis if they were unable to complete pharmacological stress testing.

### 6.1.3 Mental Stress Ischemia Mechanisms and Prognosis, Myocardial Infarction and Mental Stress (*MIMS/MIPS*)

The study design has been described prior, and is the same between the two cohorts (54). The *MIMS* cohort included participants with recent myocardial infarction within the 8 months prior to enrollment who were younger than 61 years of age at time of enrollment. The *MIPS* cohort included patients with stable CAD diagnosed via coronary angiogram, documented MI, or positive nuclear stress test. All patients underwent mental stress test and physical stress test using either treadmill or regadenosine, and were randomly assigned to complete one and then the other in two separate visits within a week. During the initial visit, medical history and psychological assessments were performed as well. During the mental stress testing, all patients had ECG recordings made of variable duration. Patients were followed longitudinally for 3-5 years for follow-up events, which were adjudicated. Patients were excluded for having acute coronary syndrome or decompensated heart failure, severe psychiatric conditions other than depression, pregnancy, uncontrolled high blood pressure, or contraindications to pharmacological stress testing.

## 6.2 Measurements

### 6.2.1 Electrocardiography Measures

In all three cohorts, ECG data was collected and analyzed using different ECG acquisition strategies and signal processing methods. As described, in the *Biobank*, ECG was collected through a single, bipolar lead using the VivaLNK patch, with data being recorded for up to 24 h. In the *Twins*, ambulatory ECG was collected through Holter monitor (GE Marquette SEER digital system; GE Medical Systems, Waukesha, Wisconsin) for 24 h. Holter monitor was also used in the *MIMS/MIPS*, however the recording time was only for several hours.

Variations in heart rate can be assessed by a number of mathematical measures, usually divided into the time and frequency domains (55). HRV was calculated through the Physionet Cardiovascular Signal Toolbox (56), which is an open-source MATLAB software for analyzing ECG signal. Time domain measures we used include the RR interval duration (converted to heart rate in beats-per-minute), the standard deviation of normally conducted RR intervals (SDNN), the root mean square of successive differences in normally conducted RR intervals (RMSSD), and the proportion of normally conducted RR intervals that differ by more than 50 ms divided by the total number of normally conducted RR intervals (PNN50). Frequency-domain measures computed through power spectral analysis categorize variability as very low frequency (VLF, 0.0033 to <0.04 Hz), low frequency (LF, 0.04 to <0.15 Hz) or high frequency (HF, 0.15 to 0.40 Hz) (57). These frequency categories reflect autonomically mediated heart rate responses to physiologic stimuli, including influences of the renin-angiotensin-aldosterone system, baroreceptor activity, and respiration (57). The sympathetic and parasympathetic nervous systems influence them to different degrees. HF reflects primarily parasympathetic nervous system activity, while LF reflects both sympathetic and parasympathetic activity (58). Total power HRV is a nonspecific global measure. RMSSD is an approximate correlate of HF, and SDNN is an approximate correlate of TP, supporting the physiological basis

of these markers.[Electrophysiology1996b] Acceleration capacity and deceleration capacity were also included where available, based on signal quality and recording length, as they also reflect clinically relevant sympathetic and vagal activity (59). These metrics are well-known as physiologic markers of acute and chronic stress, and measure slightly different aspects of autonomic nervous system function. HRV was also analyzed hourly through the commercial HeartTrends algorithm (Lev-El Diagnostics Ltd, Israel), which generated the *Dyx* measure. *Dyx* is derived from heart rate time series analysis and measures the variability and randomness of the heart rhythm. *Dyx* is generated through the multipole method analysis of Poincaré plot, in which beat-to-beat (RR) interval lengths are plotted as a function of prior RR intervals to form an ellipse, as seen in Figure B.0.1. *Dyx* is calculated as the ratio of the kurtosis along the y-axis (long-term variability) and the x-axis (beat-to-beat random variation) of the ellipse, and higher values indicate more beat-to-beat randomness and/or decreased variability (60,61).

In addition to summary and hourly assessments of HRV, diurnal rhythms were examined using cosinor metrics within the *Twins*, as seen in Figure B.0.2 (62). Morphological assessment of ECG changes were also performed in the *MIMS/MIPS* with T-wave area. The frequency domain HRV metrics were log-transformed, and then all metrics were normalized to allow for comparison.

## 6.2.2 Psychological Measures

In all cohorts, chronic psychological variables were measured through patient interviews, using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria (63) for the diagnosis of both depression and posttraumatic stress disorder (PTSD). In the *Biobank*, depressive symptoms were assessed via the 9-question Primary Care Evaluation of Mental Disorders Brief Patient Health Questionnaire (PHQ-9) (64). Moderate-severe depression is considered when the PHQ-9 score is 10 points or higher (out of 27), with this cutpoint having a sensitivity and specificity of 88% for major depression.

Within the *Twins* and *MIMS/MIPS* cohorts, depressive symptomers were assessed with Beck’s Depression Inventory, which includes 21 items with 4 statements scored 0-3, with higher scores indicating higher severity of depression (65). A cut-off of  $\geq 14$  points was used to identify patients with moderate-to-severe depressive symptom burden.

In the *MIMS/MIPS* cohort, there was a separate protocol for acute mental stress challenge. Patients were initially allowed to rest for 30 minutes in a calm, quiet, dimly lit, and temperature-regulated room. After the resting period, mental stress was induced by a standardized public speaking task, as previously described (66). The patients were asked to imagine a real-life stressful situation, such as a close relative having been mistreated in a nursing home, and then asked to make up a realistic story around this scenario. They were given two minutes to prepare the statement, and three minutes to present it in front of a video camera and an audience. The patients were told that the speech would be evaluated for content, quality, and duration.

### 6.2.3 Cardiac Measures

All cohorts underwent imaging of the heart through different modalities, which all assess complementary aspects of myocardial blood flow.

The *Biobank* used direct coronary angiography through cardiac catheterization. Obstructive CAD was defined as  $\geq 70\%$  stenosis or hemodynamic significance by fractional flow reserve. Coronary angiography was used to determine the Gensini score, which is a visual estimation of luminal narrowing in multiple segments based on a modified form of the American Heart Association classification of the coronary tree by trained cardiologists (67). Coronary angiography was also evaluated using the Coronary Artery Surgery Study (CASS), which evaluates the number of major epicardial vessels that have a certain percent stenosis, e.g. the CASS-50 score determines the number of vessels with  $\geq 50\%$  stenosis (68). Importantly, direct coronary angiography is limited to visualization of the large, epicardial conduit

vessels.

The *Twins* study used MPI using underwent MPI using nitrogen-13-ammonia positron emission tomography (PET) with adenosine as the pharmacologic stressor. Adenosine doses were calculated to induce maximal coronary vasodilation (69). Areas of diminished uptake indicate reduced capacity to maximally vasodilate, thereby causing relative coronary hypoperfusion. Images were visually interpreted by experienced cardiologists and radiologists with training in nuclear cardiology. Quantitative analysis was performed with the Emory Cardiac Toolbox to generate: a) coronary flow reserve (CFR) for absolute myocardial blood flow during stress and rest, and b) the stress total severity score (STSS), which measures the sum of the number of standard deviations below the expected value for each pixel compared to a database of normal controls (70). CFR was defined as the ratio of mean stress to rest myocardial blood flow (mL/min/g), and low CFR was defined as a ratio  $< 1.5$  (71). Abnormal MPI findings were defined as  $> 5\%$  MPI deficit. For generalizability, semi-quantitative assessments were used.

In the *MIMS/MIPS*, MPI was also used but with single-photon emission computerized tomography (SPECT), using sestamibi radio-labelled with Technetium-99. SPECT was performed at rest, after mental stress, and after physical stress (either exercise or pharmacological). Myocardial perfusion abnormalities were quantified using the Emory Cardiac Toolbox software, similar to the *Twins*, and semi-quantitative assessments were determined.

### 6.3 Sample Size and Power Considerations

The subjects for the *Biobank* were enrolled from September 2019 to February 2020, however further enrollment was limited due to the COVID-19 pandemic. It was expected that approximately 200 patients would be needed for adequate power, but due to limitations, the analyses were conducted on available data. The enrollment for *MIMS/MIPS* and *Twins* was completed prior to the initiation of this analysis,

and provided a robust population to expand upon and answer the specific aims.

## 7 Analysis

Statistical analysis was performed using R 4.0.0 (R Core Team 2020, Vienna, Austria). The analytical approach was guided by the specific aims (Section 5). ## Clinical Characteristics

In the *Biobank*, HRV was summarized over the recording length and at 15-30 minute intervals at the time of coronary angiography. In the *Twins*, HRV was computed hourly, including *Dyx*. The 24-hour data was used to generate cosinor statistics using published software (72). In the *MIMS/MIPS*, HRV was computed for each phase of the mental stress challenge. Power spectral density measures of HF, LF, and VLF HRV were log-transformed for normal distribution. Each of the clinical cohorts was described by clinical covariates, including frequency of comorbid diseases and summary statistics of continuous measures.

### 7.1 Myocardial Ischemia

The purpose of **Aim I** was to identify the relationship of autonomic dysfunction with CAD, as measured by both coronary angiography and MPI. Within the *Biobank*, summary HRV metrics were compared between those with obstructive CAD versus nonobstructive CAD using the Wilcoxon rank sum test. HRV was then assessed in a similar manner between those receiving revascularization and those that did not. HRV was segmented by timing of coronary angiography. HRV was compared at the start of catheterization (or initial intervention in those that were revascularized) to the 30 minutes before the procedure, by intervention status.

To evaluate the relationship with myocardial perfusion, HRV was also assessed within the *MIMS/MIPS* cohort, which had both mental and physical stress MPI as outcomes. Logistic regressions were used with HRV during stress and rest as the

exposures, not adjusted for clinical covariates. The area under the receiver-operator characteristic curves were generated.

$$\begin{aligned}
\text{global\_cfr}_i &\sim N(\mu, \sigma^2) \\
\mu &= \alpha_{j[i],k[i]} + \beta_1(\text{lf}) + \beta_2(\text{age}) + \beta_3(\text{bmi}) + \\
&\quad \beta_4(\text{race}_{\text{African American}}) + \beta_5(\text{race}_{\text{Asian}}) + \beta_6(\text{smoking}_1) + \beta_7(\text{prevchd}_1) + \\
&\quad \beta_9(\text{hptn}_1) + \beta_0(\text{dm}_1) \\
\alpha_j &\sim N(\mu_{\alpha_j}, \sigma_{\alpha_j}^2), \text{ for vetrid } j = 1, \dots, J \\
\alpha_k &\sim N(\gamma_0^\alpha + \gamma_1^\alpha(\text{chf}_1), \sigma_{\alpha_k}^2), \text{ for pair } k = 1, \dots, K
\end{aligned}$$

Within the *Twins*, similar analyses were performed with MPI and hourly HRV. Early morning, approximately 7 AM, HRV was used based on previous work suggesting the strong temporal relationship of HRV with clinical outcomes (26). Generalized linear mixed-effects models with Laplace approximations were used to account for clustering within twin pairs and within repeat study visits (73). Coronary flow reserve was treated as the outcome variable in linear models, and abnormal MPI was treated as the outcome variable in logistic models. With the mixed-effects model, with random effects or conditioning for both twin pair status and repeat study visits. The models were sequentially adjusted for demographic variables (age, BMI, and race), and then for cardiovascular risk factors (smoking, hypertension, cardiovascular disease). HRV was summarized as cosinor metrics of MESOR (midline estimating statistic of rhythm), amplitude, and acrophase. These metrics were treated as exposures, with CFR and MPI as outcomes, in mixed effects models as above.

## 7.2 Psychological Stress

The purpose of **Aim II** was to establish the relationship between psychological stress and autonomic dysfunction. Acute psychological stress was defined as the mental stress challenge in the *MIMS/MIPS* cohorts. Chronic psychological stress



was defined as diagnoses of depression and PTSD, and/or symptom burden.

In the *Biobank*, the distribution of HRV was compared between those with depression, as measured by PHQ-9, using Wilcoxon rank sum test. In the *Twins*, using the above described generalized linear mixed-effects models, regression analysis was performed with early morning HRV as the exposure and either PTSD or depression as the outcome. Sequential adjustment was performed for demographic factors and cardiovascular risk factors. Cosinor metrics were also used as additional exposure variables in additional mixed-models.

The *MIMS/MIPS* cohort offered the opportunity to assess both acute and chronic psychological stress. The distribution of HRV was visually compared between phases of the mental stress challenge for all subjects. HRV was then analyzed within subjects by comparing the rest phase to the both the stress and recovery phase using paired T-test. The distribution of HRV was then compared by phase in those with MSIMI and those without MSIMI using the Wilcoxon rank sum test. Logistic regression models were used with PTSD and depression as outcomes and HRV by stress phase as exposures, without adjustment, and concordance statistics were generated. Logistic regression models were then built with MSIMI as the outcome and stress HRV as the exposure, along with concordance statistics. These models were sequentially adjusted for demographic factors (age, BMI, sex, race), cardiovascular risk factors (smoking, hypertension, diabetes, hyperlipidemia), known cardiovascular disease (coronary/peripheral artery disease), and then with chronic psychological stress (depression, PTSD).

### 7.3 Clinical Outcomes

The purpose of **Aim III** was to evaluate the role of autonomic dysfunction in clinical outcomes, and understand the effect of autonomic dysfunction on the relationship between outcomes and both psychological stress and myocardial ischemia. Clinical outcomes were available in the *Twins* and *MIMS/MIPS* cohorts. Proportional hazard

assumptions were assessed visually in both cohorts.

The clinical outcomes of interest were overall mortality and death by cardiovascular disease in the *Twins*. Early morning HRV was treated as the exposure, with the survival time before censoring event as the outcome in Cox proportional hazard models. The models were sequentially adjusted for myocardial ischemia, demographic factors (age, BMI, race), cardiovascular factors (known cardiovascular disease, hypertension, diabetes, smoking), and psychological factors (depression, PTSD). In a similar fashion, cosinor metrics for HRV were used as exposure variables in models that were sequentially adjusted as above.

In the *MIMS/MIPS*, the clinical outcomes of interest were overall mortality, cardiovascular mortality, and recurrent cardiovascular events including myocardial infarction or revascularization. Cox proportional hazard models were used for both overall and cardiovascular mortality. Recurrent event analysis used proportional hazard models with strata for events and individuals using marginal models, Prentice-Williams-Peterson models (both total and gap time), and Anderson-Gill models (74). These models were sequentially adjusted for demographic factors (age, BMI, sex, race), cardiovascular risk factors (smoking, hypertension, diabetes, hyperlipidemia), known cardiovascular disease (coronary/peripheral artery disease), and then with chronic psychological stress (depression, PTSD).

# RESULTS

## 8 Study Overview

The study populations in the three cohorts are uniquely suited for these analyses. They are complementary in their description of cardiovascular disease, autonomic function, and psychological factors, and are described here.

The *Biobank* cohort, as described in Table A.1.2, had 56 participants, with a mean (95% CI) age in years of 62 (52, 70). 9 (17%) were female, and 14 (26%) were Black. There were 34 (71%) that had obstructive CAD on coronary angiography, and 10 (21%) had depression.

The *MIMS/MIPS* cohort had 958 participants. The mean age was 59 (52, 68), 323 (34%) were female, and 385 (41%) were Black. 700 (84%) had obstructive CAD. 273 (30%) had a diagnosis of depression, and 87 (9.5%) had a diagnosis of PTSD. In this population, 238 (25%) had MSIMI. Additional breakdown by study group is described in ??.

The *Twins* cohort, as described in both Table A.1.3 and A.1.5, had 1012 participants over 4 follow-up visits, with 610 unique participants. The mean age was 55.0 (52.0, 57.0) during the initial enrollment period, and was 68.4 (66.8, 69.5) during the final enrollment period. All participants were male, and 95.75% were White. The average rate over the enrollment periods of abnormal MPI was 12.13%. The average rate of PTSD was 16.52% and the average rate of depression was 13.38%. Of note, as these patients were enrolled for recurrent visits, there is a trend towards decreasing HRV over time, most prominent with LF HRV, which has been noted in the literature (75,76).

## 9 Psychological Stress

Acute mental stress was assessed primarily using the *MIMS/MIPS* cohorts. The distribution of HRV metrics based on the phase of acute mental stress challenge was evaluated, as seen in Figure A.2.1. There were only small differences between stress and rest HRV, as seen in Table A.2.2. The difference in distribution of HRV was compared between those that had MSIMI and those that did not, as described in A.3.7. There was a decrease in HRV in those with MSIMI compared to those without, except with heart rate.

The association between HRV during acute mental stress and chronic mental stress was also assessed (Table A.2.3). Every 1 standard deviation (SD) increase in resting heart rate had an OR = 1.43 (95% CI 1.14, 1.78) for PTSD and an OR = 1.19 (95% CI 1.02, 1.39) for depression. Every 1 SD increase in LF HRV during recovery had an OR = 0.82 (95% CI 0.67, 1.02) for depression. No other HRV metrics were strongly associated.

Chronic psychological stressors were analyzed using all three cohorts. In the *Biobank* cohort, there were no significant differences seen in HRV by depressive symptoms as measured on the PHQ-9 (Table A.2.4).

In the *Twins*, early morning HRV was measured against both PTSD and depression. There was a significant relationship between HRV and both depression and PTSD as seen in Table A.2.5. In adjusted logistic models for PTSD, every 1 SD increase in HF HRV had an OR = 0.54 (95% CI 0.37, 0.78), and LF HRV had an OR = 0.49 (95% CI 0.32, 0.76). In adjusted models logistic models for depression, every 1 SD of increase in VLF HRV had an OR = 0.18 (95% CI 0.09, 0.36). *Dyx* and VLF HRV were not strongly associated with PTSD.

When assessing circadian autonomic variability, measured by cosinor analysis,

significant relationships were seen with both depression and PTSD in the MESOR and amplitude (Table A.2.6). For example, every 1 SD increase in the MESOR of LF HRV had an OR = 0.46 (95% 0.3, 0.69) and every 1 SD increase in the amplitude had an OR = 0.33 (95% 0.15, 0.75) for PTSD. Every 1 SD increase in the MESOR of LF HRV had an OR = 0.25 (95% 0.14, 0.45) and every 1 SD increase in the amplitude had an OR = 0.29 (95% 0.13, 0.66) for depression.

## 10 Myocardial Ischemia

The relationship of short-term autonomic metrics to CAD as measured by coronary angiography was assessed in the *Biobank* cohort. When comparing summary HRV metrics between those with obstructive CAD versus nonobstructive CAD, there were no significant differences between HRV distributions (A.3.1). When comparing those that had revascularization of the CAD and those that did not (A.3.2), there was a difference seen in RR interval. Those that underwent revascularization had a mean (95% CI) RR interval of 0.59 (-0.06, 0.81), while those that did not had a mean RR interval of 0.01 (-0.69, 0.48). There was a trend towards an increased *Dyx* in those that underwent revascularization (2.27 (1.61, 2.82)) than those that did not (1.72 (1.27, 2.15)). No other HRV metrics were associated with revascularization. To effect of the timing of revascularization on the subsequent changes in HRV acutely were assessed, as described in Table A.3.3. No differences were seen between HRV before or after cardiac catheterization.

The relationship of stress reactivity autonomic metrics to myocardial perfusion was assessed using both mental stress and physical stress in the *MIMS/MIPS* cohorts. ECG and HRV metrics did not have an association with abnormal MPI with combined mental and physical stress nor with physical stress. Both HF HRV and LF HRV most prominently had an association with MSIMI, with stress HRV HRV having an odds ratio (OR) = 0.77 (95% CI 0.65, 0.9) and LF HRV having an OR = 0.77 (95% CI 0.66, 0.91). The other associations are described in Table A.3.4.

This relationship between myocardial perfusion and early morning autonomic metrics was further explored using quantitative MPI in the *Twins* cohort. Morning HRV at approximately 7 AM was predominately associated with coronary flow reserve, as described in Table A.3.5. A change in 1 SD of LF HRV was associated with an 1.15 (95% CI 1.03, 1.28) in adjusted models. *Dyx* had an OR = 0.75 (95% CI 0.58, 0.98)

for abnormal MPI.

Within the *Twins*, circadian autonomic variability was measured using cosinor analysis. The relationship of the MESOR, amplitude, and acrophase with abnormal MPI and coronary flow reserve were evaluated (Table A.3.6). The MESOR in particular showed a consistent relationship with coronary flow reserve, with a 0.89 (0.58, 1.36) increase in every 1 SD increase in LF HRV, and a 0.91 (0.67, 1.24) increase for every 1 SD increase in  $Dyx$ .

To assess the relationship of acute mental stress with myocardial perfusion abnormalities, the relationship between HRV and MSIMI was assessed. As seen in Table A.3.8, there was a robust association between LF and HF HRV during rest and stress with MSIMI. In fully adjusted models, including adjustment for both cardiovascular and psychological risk factors, every 1 SD increase in stress HF HRV had an OR = 0.76 (95% CI 0.64, 0.91) and stress LF HRV had an OR = 0.76 (95% CI 0.68, 0.97) for MSIMI.



## 11 Clinical Outcomes

Clinical outcome data was available in both the *Twins* and the *MIMS/MIPS* cohorts. With the *Twins*, early morning autonomic metrics showed a robust association with overall mortality and with cardiovascular disease, as seen in Table A.4.1. In fully adjusted models for overall mortality,  $Dyx$  and VLF HRV had the strongest association. With every 1 SD of increase in  $Dyx$ , there was a hazard ratio (HR) = 0.49 (95% CI 0.34, 0.7), and with every 1 SD increase in VLF HRV, there was a HR = 0.48 (95% CI 0.23, 0.99). When evaluating the relationship of circadian autonomic variability and clinical outcomes,  $Dyx$  was a significant predictor of both overall and cardiovascular mortality. The MESOR of  $Dyx$  had a HR = 0.42 (95% CI 0.28, 0.62) and the amplitude of  $Dyx$  had a HR = 0.5 (95% CI 0.3, 0.83). Further relationships are outlined in A.4.2.

Using the *MIMS/MIPS* cohorts, stress reactivity autonomic metrics were compared with clinical outcomes. There was a robust relationship between stress HRV and overall mortality, cardiovascular mortality, and recurrent cardiovascular events as described in Table A.4.3. In fully adjusted models for cardiovascular mortality, including primary adjustment for MSIMI, 1 SD increase in stress LF HRV had a HR = (95% CI , ) and HF HRV had a HR = (95% CI , ).

# DISCUSSION

## 12 Principal Findings

Our series of neurocardiac examinations in three distinct cohorts to describes multifaceted relationships amongst the autonomic physiology, psychological stress, and cardiovascular disease. The use of cohorts with varied levels of cardiovascular risk allowed for specific testing of the hypothetical pathways between stress and cardiovascular disease, and leveraged the importance of stress reactivity with clinical outcomes, as described in Section 5. We found that autonomic dysfunction was strongly related to psychological stress, and that autonomic changes to stressors was associated with abnormalities in myocardial perfusion. The autonomic response to stress was moreover strongly associated with clinical outcomes and increased mortality. We believe these findings support autonomic dysfunction as an important clinical manifestation of both psychological and cardiovascular disease. We summarize the major findings below.

### 12.1 Psychological Stress

In **Aim I**, we studied the potential autonomic mechanisms that may underlie both acute and chronic mental stress. Our most important finding was that both depression and PTSD were associated with not only with acute changes in HRV, but pervasive changes to the overall circadian rhythm, with dampened HRV measurements throughout the day. Psychological stress has an increased risk of cardiovascular mortality beyond that of maladaptive health behaviors (14,15). Both depression and PTSD show an excess risk of cardiovascular disease that cannot be explained by symptom burden (23,77). Stress and its effect on autonomic function may play a role in this excess risk (78), thus our aim to study underlying autonomic mechanisms may help to explain this disparity. Our findings suggests a pervasive effect of chronic psychiatric disorders on autonomic physiology that warrants further exploration,

particularly relevant as they can be measured through non-invasive, ubiquitous ECG-based tools. As psychiatric disease and life stress are both highly prevalent and likely under recognized, these measures may allow us to diagnose and manage autonomic dysfunction more readily.

We found that within subjects, there were only small difference in autonomic metrics in response to acute stress, with return towards baseline during recovery. Heart rate, as expected, increased during acute stress, and both HF and LF HRV decreased in power. On the other hand, T wave area remained persistently decreased during recovery as compared to rest. This suggests that the autonomic mechanisms at hand have a range of effects of differing duration, with electrical and morphological changes being the more persistent, and frequency-domain metrics, such as HF HRV, being the more rapid. Even shorter-term HRV metrics have been used, recorded under  $< 1$  minute, and have shown differences for mental stress activities during daily living (78), however the clinical importance of this is unknown. Our approach and findings are more robust due to the controlled experimental environment, measurement during recovery, and ability to adjust for relevant clinical covariates. The likely mechanism that occurs during acute mental stress is sympathetic activation and parasympathetic withdrawal. These findings allow us to utilize the ECG-based response to stress as an additional exposure for neurocardiac disease and clinical outcomes.

We sought to identify if the change in autonomic function in response to acute stress would associate with the chronic mental stress of depression or PTSD. We found that elevated resting heart rate was associated with both psychiatric diseases, and decreases in LF HRV during recovery were associated with only depression. This was contrary to what we expected, as there is a known relationship of HRV with both depression and PTSD (51,79). Prior studies have shown the relationship of HRV and depression with longer-duration ECG recordings, such as 24 hour Holter monitor (80). Our findings are most likely limited by the short duration of recordings. Autonomic modulation is a dynamic phenomenon, and by measuring during stress and recovery, the underlying abnormalities may be suppressed.

We were able to ask this question about the relationship of autonomic dysfunction and chronic mental stress using longer term recordings. We found that HRV, particularly during early morning hours, was more robustly associated with HRV. The strongest association for depression was LF and VLF HRV, and for PTSD was acceleration capacity and HF and LF HRV. Although these associations are supported in the literature (51,80), our findings are unique in that they were selected at purely early morning hours. Due to the auto-regressive nature of ECG signal, 24 hour data could not easily be assessed in a similar manner, and thus cosinor analysis was performed (72). We evaluated circadian autonomic variability and found a much more robust relationship between autonomic function and both depression and PTSD. The global or equatorial measure of autonomic tone, described by the MESOR, and the overall amplitude of autonomic tone, were decreased in patients with both depression and PTSD with frequency-domain HRV and acceleration capacity. *Dyx* variability had less changes in amplitude than other variables. There were no changes in the acrophase, best described as the time to peak amplitude of the signal, in any of these measures. This suggest that the relationship between autonomic function and psychiatric disease may more strongly have circadian characteristics than previously thought (81,82). Depressive symptom burden, for example, has a level of diurnal variation (83), which may be quantified by autonomic metrics.

## 12.2 Myocardial Ischemia

In **Aim II**, we studied the autonomic mechanisms underlying ischemic heart disease. Our two most important findings were that autonomic responses to acute stress were strongly associated with MSIMI, and that circadian autonomic variability was associated with coronary flow reserve. This supports that important role autonomic regulation plays in cardiovascular physiology, and provides insight into a different facet of IHD. IHD is not fully understood, as half of sudden cardiac deaths occur in men and women without known cardiovascular disease (84–86). There are important levels to the coronary artery system, including epicardial

conduit vessels and the myocardial resistance vessels. The difference between the two has started to become more clinically relevant as we begin to understand that myocardial ischemia is not only a problem of epicardial atherosclerotic disease (71). The ANS however has been implicated for its prominent role in regulation of cardiac electrophysiology, contractility, coronary vasomotor tone, amongst other effects (29). Both macrovascular and microvascular systems are heavily innervated and respond to different autonomic inputs, and also have afferent systems, allowing for bidirectional communication (27). Thus, understanding the differences and quantifying the effect of autonomic dysfunction as it relates to myocardial ischemia will help us to better understand and differentiate between these diseases burdens and their corresponding increased risks. Clinically, understanding the role of autonomic dysfunction in coronary regulation allows us to study and elucidate novel mechanisms in myocardial blood flow that are not yet understood. It also adds to our ability to assess the risk of coronary artery disease, providing an additional non-invasive, ECG-based tool to further risk stratify patients.

By assessing obstructive CAD through direct angiography, we were able to assess purely epicardial disease. We found no strong relationship between short-term autonomic metrics and obstructive CAD, however there was a trend towards higher  $Dyx$  in subjects with obstructive CAD. We found that those who underwent revascularization had a lower heart rate than those who did not, and similarly,  $Dyx$  trended higher in those patients than those without revascularization. This is a counterintuitive finding, in that literature there has been increasing support that HRV metrics such as  $Dyx$  may correlate with abnormal stress tests (26,42,87). However, in these studies, subjects had no known CAD, and were of low to intermediate pretest probability. The subjects we found with obstructive CAD would have been excluded, which may explain the findings or that obstructive CAD may modify autonomic tone in a non-linear manner.

We extended the prior analysis to review short-term autonomic metrics during the process of revascularization. During revascularization, we compared the time after

initial angioplasty to the 30 minutes preceding the case. We found no differences between HRV before or after cardiac catheterization was initiated, regardless of revascularization was performed. This finding is even more surprising in that revascularization is known to lead to autonomic changes immediately, such as an increased transient risk for ventricular arrhythmias (88) This may be based on the chronicity of the epicardial disease, as a majority of these subjects were outpatient at the time of catheterization.

We evaluated the epicardial vessels through myocardial perfusion, using either exercise or pharmacological stress, and assessed the relationship with autonomic function. We used acute stress changes, early morning changes, and circadian autonomic variability as metrics of autonomic tone. We found that short-term recordings of autonomic metrics had no association with physical stress-induced myocardial ischemia (PSIMI), either at rest, stress, or during recovery. When we extended the recording duration to 1 hour, selected at 7 AM based on prior findings (26), we found associations primarily with *Dyx*, even after adjustment for cardiovascular risk factors and known cardiovascular disease. When using the full 24 hour recording, there were no prominent relationships with abnormal MPI. These findings do show a pattern that increased *Dyx* decreases the risk for having an abnormal MPI, which is similar in that of the ECG metrics available, it is the only one to show a consistent relationship with suspected epicardial disease. However, the relationship is inverse than that of the findings of obstructive CAD on angiography, which begs the question of the mechanism by which *Dyx* is associated with epicardial disease.

To fully delineate the pathways involved in IHD, we evaluated the myocardial blood flow through coronary flow reserve, and assessed the relationship with autonomic dysfunction as previously. Using quantitative PET, we were able to measure coronary flow reserve, which may be related by the autonomic activity (89). We found that early morning autonomic metrics were reliably related to CFR, even after adjustment for traditional risk factors. The most prominent association was with LF HRV and the other frequency-domain HRV metrics. When evaluated using circadian autonomic

variability, the relationship was consistent, and showed not only a relationship with the MESOR, but also that of the amplitude. These findings suggest that CFR, as compared to MPI, may be more regulated by autonomic tone, which supports the circadian distribution of major adverse cardiovascular events (47).

The relationship of stress reactivity and myocardial perfusion was systematically assessed to understand if there were common, autonomic mechanisms underlying both. By measuring HRV during acute mental stress challenge, we were able to uniquely measure stress reactivity autonomic metrics. This marker was used as a predictor for the development of mental stress-induced myocardial ischemia (MSIMI). We found that HRV, but not heart rate or T wave area, was significantly lower in those with MSIMI, particularly during the stress phase. We found a robust association in logistic models, particularly with HF and LF HRV during stress, for the risk of MSIMI. Every 1 unit increase in HRV led to approximately half the risk of MSIMI. Even when adjusted for cardiovascular risk factors, the relationship remained robust, and was unchanged by the inclusion of chronic mental stress variables of PTSD and depression. This finding is the first of its kind, as it shows a direct relationship between MSIMI and autonomic dysfunction in a non-invasive, quantifiable manner, and highlights the important autonomic mechanisms underlying MSIMI.

## 12.3 Clinical Outcomes

In **Aim III**, we sought to understand the autonomic mechanisms underlying the risk of MACE. We found that the autonomic response to acute stress and circadian rhythms leads to an increased risk for MACE. In large, population studies, LF HRV has been seen to associate with an increased risk for overall mortality (75,90). Autonomic dysfunction has become an increasingly recognized additional risk factor for overall cardiovascular mortality (91). Certain measures, such as *Dyx* have even shown increased mortality after myocardial infarction similar in effect to that of decreased ejection fraction (41). This suggests that autonomic testing is just at its nascency at helping to predict cardiovascular events (92).



We examined the utility of a early morning autonomic metrics with both overall and cardiovascular mortality. We found that both LF and VLF HRV were consistently associated with mortality, however *Dyx* was the most prominent marker of outcomes. When measuring circadian autonomic variability, the MESOR of both LF and VLF HRV were both strongly associated with mortality. *Dyx* once again was most strongly associated, with a robust relationship of both MESOR and amplitude. Heart rate was also seen to be related, both through MESOR and amplitude, with increased heart rate leading to increased mortality, with decreased amplitude associated with decreased mortality. These findings were robust through adjustment of abnormal MPI, cardiovascular risk factors, known IHD, as well as chronic mental stress. This supports the idea that autonomic dysfunction is a unique, independent risk factor for mortality. The relationship of autonomic function with mortality reflects that changes in diurnal rhythm is a clinical important entity, and either may predict or share a common pathology that leads to increased cardiovascular risk.

Similar to circadian changes, acute mental stress may serve as a method to elicit autonomic dysfunction. This type of autonomic dysfunction may also increase risk for MACE. We found that stress reactivity autonomic metrics were a robust predictor of not only cardiovascular death, but also recurrent cardiovascular events, with a hazard ratio ranging from 0.3 – 0.5. When adjusted for MSIMI, there was no change in the effect size of stress HRV on mortality or recurrent MACE, and MSIMI was not found to be a significant covariate. These findings were similar after adjustment for cardiovascular disease and risk factors, as well as chronic mental stress. This suggests that not only does HRV strongly associate with MSIMI, but explains the known increased cardiovascular risk that is associated with MSIMI. This supports the concept that autonomic dysfunction is related to MSIMI and may explain its increased risk of mortality, and is likely the mechanism by which MSIMI occurs (93).

## 13 Limitations and Future Direction

Each of the cohorts had unique strengths and limitations. First, the generalizability of these findings is somewhat limited, in that the populations had different baseline characteristics, such as frequency of CAD, sex, and age. ECG metrics are likely not able to be compared between groups due to these class differences. However, there is some evidence that HRV is not readily made to be standardized across populations (94), and there may be reason to compare findings within an individual instead. Globally, the method of sampling of ECG signal and the generation of HRV is fraught with potential errors, including interpolation methods, signal duration, noise. ECG signal was also recorded using different technologies, from the VivaLNK ECG patch to single and multi lead Holter monitors. Our signal recordings between cohorts is not of a similar length, thus the exact metrics, such as cosinor analysis, could not be used equivalently between groups. The amount of noise, differences in sampling frequencies, and overall quality led to exclusion of signal that was considered unusable. These are common errors faced by researchers within the field, which we minimized using standardized, open-source techniques (56). However, as we have worked through these errors in prior studies, there is confidence that there are similar patterns between groups even with the cohort variability.

Chronic psychological stress was measured in the binary form of a single diagnosis. Treating depression and PTSD as continuous variables may have provided a more useful outcome in assessing the effect of autonomic dysfunction but was limited by the frequency of symptom burden. In addition, symptom burden was assessed differently between cohorts, such as using the PHQ-9 in the *Biobank* and Beck's Depression Inventory in the *Twins*. However, the correlation between the two forms are high, and allow for some level of generalizability and extrapolation of autonomic function to its relationship with depressive symptom burden.

This is similar to limitations in assessing CAD, in that each cohort used a separate method for assessing myocardial perfusion, from direct coronary angiography to PET and SPECT. Coronary artery calcium was not available in nuclear imaging, thus confirming the presence of epicardial coronary disease was not possible. Additional factors, such as prior coronary revascularization, reason for angiography, and clinical context, were not able to be accounted for as easily due to the limited number of events. At the same time, the differences in imaging modalities assesses different components of neurocardiac axis, from epicardial disease to microvascular disease, giving a more nuanced understanding of cardiovascular physiology.

Clinically, although the follow-up events were adjudicated, primary data on the cause of death was not always able to be obtained. Between cohorts, cardiovascular events were not necessarily measured in the same way, such as recurrent events recorded in the *MIMS/MIPS* cohort, but only initial events in the *Twins*. In addition, follow-up data may have led to conflicting or overlapping events, such as onset of atrial fibrillation during hospitalization for decompensated heart failure, and based on the modeling approaches used, we would not be able to control for same-day events. However, the use of recurrent events was strengthened particularly by using a series of recurrent event modeling approaches, all with similar findings suggesting a robust and persistent relationship with autonomic dysfunction and clinical outcomes.

The largest strengths of this study are the use of multiple cohorts, the rigor applied to each hypothesis, and advanced statistical techniques to control for confounding, such as mixed effects models to control for twins. The ability to share similar ECG metrics between cohorts also allowed for some translation of study findings between groups.

This study reveals a number of important clinical questions. Autonomic changes may not only associate with overall depression or PTSD, but may also precede or correlate with changes in symptom burden, or may an intervenable metric to help control symptoms, such as with biofeedback (95). Autonomic dysfunction appears to have a strong association with coronary microvascular dysfunction. Assessing microvascular

dysfunction during coronary angiography with intracoronary acetylcholine, or through cardiac magnetic resonance imaging, may allow for more precise measurements of coronary flow reserve, and provide a higher fidelity metric for comparison. In addition to baseline HRV predicting future adverse events, repeat HRV metrics would be helpful to assess autonomic function as a dynamic variable that may change over time. This could be expanded to include interventions aimed at improving autonomic function, from cognitive behavioral therapy to vagal nerve stimulation, which would help to assess the role of autonomic dysfunction as a modifiable risk factor. The study of the neurocardiac axis is likely in its infancy, with significant room for expansive questions to help tackle this challenging field.

# CONCLUSIONS

The objective of this study was to evaluate how stress reactivity effects cardiovascular disease and clinical outcomes. By leveraging several methods of assessing stress, as described in the specific aims, we were able to assess the relationship of stress with autonomic dysfunction along the neurocardiac axis. We were able to demonstrate the association of autonomic metrics with both psychological stress and myocardial ischemia, and using nuanced differences between our datasets, evaluate specific components of psychological stress and coronary artery disease.

The most prominent finding was the relationship of autonomic metrics with MSIMI. This ties together the effect of acute mental stress on myocardial ischemia through autonomic mechanisms that are readily quantifiable. Not only is there a relationship with MSIMI, but autonomic dysfunction in response to stress may in fact mediate the increased mortality seen with MSIMI. An additional important discovery was the relationship of circadian autonomic variability to abnormal myocardial blood flow, psychological stress, and overall clinical outcomes. This diurnal pattern supports the known circadian pattern of MACE, most commonly seen between 6 AM and 10 AM, and subsequently between 6 PM and 8 PM (47).

These findings are part and parcel of a quantifiable approach to measuring stress reactivity, supporting the clinical significance on multiple levels of the neurocardiac axis, including mortality. The next steps will be to identify if the autonomic response to stress can be modulated, and whether this will lead to decreases in cardiovascular disease, psychological distress, and overall mortality.

# REFERENCES

1. Zipes DP, Rubart M. Neural modulation of cardiac arrhythmias and sudden cardiac death. *Heart Rhythm* [electronic article]. 2006;3(1):108–113. (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566299/pdf/nihms67338.pdf><http://www.ncbi.nlm.nih.gov/pubmed/18540155><http://linkinghub.elsevier.com/retrieve/pii/S1547527105021399>)
2. Lown B. Sudden cardiac death: The major challenge confronting contemporary cardiology. *The American Journal of Cardiology*. 1979;43(2):313–328.
3. Carney RM, Freedland KE, Miller GE, et al. Depression as a risk factor for cardiac mortality and morbidity: A review of potential mechanisms. In: *Journal of psychosomatic research*. 2002:897–902.
4. Boscarino JA. A prospective study of ptsd and early-age heart disease mortality among vietnam veterans: Implications for surveillance and prevention. *Psychosomatic Medicine* [electronic article]. 2008;70(6):668–676. (<https://insights.ovid.com/crossref?an=00006842-200807000-00007><http://www.ncbi.nlm.nih.gov/pubmed/18596248><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3552245>)
5. Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. *JAMA*. 2017;317(15):1517.
6. McAloon CJ, Boylan LM, Hamborg T, et al. The changing face of cardiovascular disease 2000–2012: An analysis of the world health organisation global health estimates data. 2016;224:256–264.
7. Jha MK, Qamar A, Vaduganathan M, et al. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. 2019;73:1827–1845. (<http://www.ncbi.nlm.nih.gov/pubmed/30975301>)
8. Meijer A, Conradi HJ, Bos EH, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: A meta-analysis of 25 years of research. *General Hospital Psychiatry*. 2011;33(3):203–216.
9. Davis AM, Natelson BH. Brain-heart interactions. The neurocardiology of arrhythmia and sudden cardiac death. *Texas Heart Institute journal* [electronic article]. 1993;20(3):158–69. (<http://www.ncbi.nlm.nih.gov/pubmed/8219819><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC325088>)
10. La Rovere MT, Bigger JT, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. *Lancet* [electronic article]. 1998;351(9101):478–484. (<http://www.ncbi.nlm.nih.gov/pubmed/9482439>)



11. Stein PK, Carney RM, Freedland KE, et al. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. *Journal of Psychosomatic Research*. 2000;48(4-5):493–500.
12. Carney RM, Freedland KE, Veith RC. Depression, the autonomic nervous system, and coronary heart disease. 2005;67:S29–S33. (<https://insights.ovid.com/crossref?an=00006842-200505001-00008>)
13. Sassi R, Cerutti S, Lombardi F, et al. Advances in heart rate variability signal analysis: Joint position statement by the e-Cardiology ESC Working Group and the European Heart Rhythm Association co-endorsed by the Asia Pacific Heart Rhythm Society. *Europace* [electronic article]. 2015;17(9):1341–1353. (<https://academic.oup.com/europace/article-abstract/17/9/1341/627516>)
14. Steptoe A, Kivimäki M. Stress and cardiovascular disease. 2012;9:360–370. ([www.nature.com/nrcardio](http://www.nature.com/nrcardio))
15. Steptoe A, Shankar A, Demakakos P, et al. Social isolation, loneliness, and all-cause mortality in older men and women. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110(15):5797–5801.
16. Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary artery disease in men: The precursors study. *Archives of Internal Medicine* [electronic article]. 1998;158(13):1422–1426. (<http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte.158.13.1422>)
17. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). *Journal of Clinical Psychiatry*. 2015;76(2):155–162.
18. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics - 2018 update: A report from the American Heart Association. *Circulation*. 2018;137(12):E67–E492.
19. Carney RM, Freedland KE. Depression and coronary heart disease. 2017;14:145–155. (<http://www.ncbi.nlm.nih.gov/pubmed/27853162><http://www.nature.com/articles/nrcardio.2016.181>)
20. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: Systematic review and recommendations: A scientific statement from the american heart association. 2014;129:1350–1369.
21. Berkman LF, Blumenthal J, Burg M, et al. Effects of Treating Depression and Low Perceived Social Support on Clinical Events after Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. *Journal of the American Medical Association*. 2003;289(23):3106–3116.

22. Kronish IM, Moise N, Cheung YK, et al. Effect of Depression Screening after Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial. *JAMA Internal Medicine*. 2019;
23. Smolderen KG, Buchanan DM, Gosch K, et al. Depression Treatment and 1-Year Mortality after Acute Myocardial Infarction: Insights from the TRIUMPH Registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status). *Circulation* [electronic article]. 2017;135(18):1681–1689. (<https://www.ncbi.nlm.nih.gov.proxy.library.emory.edu/pmc/articles/PMC5796757/pdf/nihms859462.pdf>)
24. Shah AS, Alonso A, Whitsel EA, et al. Association of Psychosocial Factors With Short-Term Resting Heart Rate Variability: The Atherosclerosis Risk in Communities Study. *Journal of the American Heart Association* [electronic article]. 2021;10(5):e017172. (<http://www.ncbi.nlm.nih.gov/pubmed/33631952>)(<https://www.ahajournals.org/doi/10.1161/JAHA.120.017172>)
26. Shah AS, Shah AJ, Lampert R, et al. Alterations in heart rate variability are associated with abnormal myocardial perfusion. *International Journal of Cardiology* [electronic article]. 2020;305:99–105. (<https://linkinghub.elsevier.com/retrieve/pii/S0167527319355214>)(<http://www.ncbi.nlm.nih.gov/pubmed/32024598>)
26. Shah AS, Shah AJ, Lampert R, et al. Alterations in heart rate variability are associated with abnormal myocardial perfusion. *International Journal of Cardiology* [electronic article]. 2020;305:99–105. (<https://linkinghub.elsevier.com/retrieve/pii/S0167527319355214>)(<http://www.ncbi.nlm.nih.gov/pubmed/32024598>)
27. Armour JA. Myocardial ischaemia and the cardiac nervous system. *European heart journal* [electronic article]. 1999;16(12):1751–2. (<https://academic.oup.com/cardiovascres/article-abstract/41/1/41/317013>)(<http://www.ncbi.nlm.nih.gov/pubmed/8681998>)
28. Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. *Circulation* [electronic article]. 1990;82(4):1095–1105. (<http://circ.ahajournals.org/>)(<https://www.ahajournals.org/doi/10.1161/01.CIR.82.4.1095>)
29. Abboud FM, Thames MD. Interaction of Cardiovascular Reflexes in Circulatory Control. *Comprehensive Physiology* [electronic article]. 2011;675–753. (<https://onlinelibrary-wiley-com.proxy.library.emory.edu/doi/pdf/10.1002/cphy.cp020319>)(<http://doi.wiley.com/10.1002/cphy.cp020319>)
30. Veith RC, Lewis N, Linares OA, et al. Sympathetic Nervous System Activity in Major Depression: Basal and Desipramine-Induced Alterations in Plasma Norepinephrine Kinetics. *Archives of General Psychiatry*. 1994;51(5):411–422.

31. Hughes JW, York KM, Li Q, et al. Depressive symptoms predict heart rate recovery after exercise treadmill testing in patients with coronary artery disease: Results from the psychophysiological investigations of myocardial ischemia study. *Psychosomatic Medicine*. 2008;70(4):456–460.
32. Davydov DM, Shapiro D, Cook IA, et al. Baroreflex mechanisms in major depression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2007;31(1):164–177.
33. Minisi AJ, Thames MD. Activation of cardiac sympathetic afferents during coronary occlusion. Evidence for reflex activation of sympathetic nervous system during transmural myocardial ischemia in the dog. *Circulation* [electronic article]. 1991;84(1):357–367. (<http://circ.ahajournals.org/%20https://www.ahajournals.org/doi/10.1161/01.CIR.84.1.357%20http://www.ncbi.nlm.nih.gov/pubmed/2060106>)
34. Pauziene N, Alaburda P, Rysevaite-Kyguoliene K, et al. Innervation of the rabbit cardiac ventricles. *Journal of Anatomy* [electronic article]. 2016;228(1):26–46. (<https://www.ncbi.nlm.nih.gov.proxy.library.emory.edu/pmc/articles/PMC4694158/pdf/JOA-228-026.pdf>)
35. Ardell JL, Armour JA. Neurocardiology: Structure-Based function. *Comprehensive Physiology* [electronic article]. 2016;6(4):1635–1653. (<https://onlinelibrary-wiley-com.proxy.library.emory.edu/doi/pdf/10.1002/cphy.c150046>)
36. Schwartz PJ, De Ferrari GM, Pugliese L. Cardiac sympathetic denervation 100 years later: Jonnesco would have never believed it. *International Journal of Cardiology* [electronic article]. 2017;237:25–28. (<http://dx.doi.org/10.1016/j.ijcard.2017.03.0200167-5273/>)
37. Penninx BWJH. Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms. 2017;74:277–286. (<http://dx.doi.org/10.1016/j.neubiorev.2016.07.003>)
38. Zhang Y, Mazgalev TN. Arrhythmias and vagus nerve stimulation. *Heart Failure Reviews*. 2011;16(2):147–161.
39. Gurel NZ, Carek AM, Inan OT, et al. Comparison of autonomic stress reactivity in young healthy versus aging subjects with heart disease. *PLoS ONE* [electronic article]. 2019;14(5):e0216278. (<http://dx.plos.org/10.1371/journal.pone.0216278>)
40. Saul J. Beat-To-Beat Variations of Heart Rate Reflect Modulation of Cardiac Autonomic Outflow. *Physiology* [electronic article]. 1990;5(1):32–37. (<http://www.physiology.org/doi/10.1152/physiologyonline.1990.5.1.32>)

41. Jørgensen RM, Abildstrøm SZ, Levitan J, et al. Heart Rate Variability Density Analysis (Dyx) and Prediction of Long-Term Mortality after Acute Myocardial Infarction. *Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc* [electronic article]. 2016;21(1):60–68. (<http://onlinelibrary.wiley.com/doi/10.1111/anec.12297/full%5Cnpapers3://publication/doi/10.1111/anec.12297>)
42. Goldkorn R, Naimushin A, Shlomo N, et al. Comparison of the usefulness of heart rate variability versus exercise stress testing for the detection of myocardial ischemia in patients without known coronary artery disease. *American Journal of Cardiology* [electronic article]. 2015;115(11):1518–1522. ([https://ac-els-cdn-com.proxy.library.emory.edu/S000291491500898X/1-s2.0-S000291491500898X-main.pdf?\\_tid=6dcdce40-a31f-11e7-a283-00000aacb35d&acdnat=1506474284\\_e7b6913530ad6e0b9cd4b3c10e770803](https://ac-els-cdn-com.proxy.library.emory.edu/S000291491500898X/1-s2.0-S000291491500898X-main.pdf?_tid=6dcdce40-a31f-11e7-a283-00000aacb35d&acdnat=1506474284_e7b6913530ad6e0b9cd4b3c10e770803))
43. Petrowski K, Wichmann S, Siepmann T, et al. Effects of Mental Stress Induction on Heart Rate Variability in Patients with Panic Disorder. 2016;42:1–10. (<http://www.ncbi.nlm.nih.gov/pubmed/27889892%20http://link.springer.com/10.1007/s10484-016-9346-9>)
44. Arri SS, Ryan M, Redwood SR, et al. Mental stress-induced myocardial ischaemia. *Heart* [electronic article]. 2016;102(6):472–480. ([http://heart.bmj.com/%20http://link.springer.com/10.1007/978-3-319-32480-7\\_8%20http://heart.bmj.com/lookup/doi/10.1136/heartjnl-2014-307306](http://heart.bmj.com/%20http://link.springer.com/10.1007/978-3-319-32480-7_8%20http://heart.bmj.com/lookup/doi/10.1136/heartjnl-2014-307306))
45. Vaccarino V, Sullivan S, Hammadah M, et al. Mental stress-induced-myocardial ischemia in young patients with recent myocardial infarction: Sex differences and mechanisms. *Circulation* [electronic article]. 2018;137(8):794–805. (<http://ahajournals.org%20http://www.ncbi.nlm.nih.gov/pubmed/29459465%20http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5822741%20https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.030849>)
46. Castaldo R, Melillo P, Bracale U, et al. Acute mental stress assessment via short term HRV analysis in healthy adults: A systematic review with meta-analysis. *Biomedical Signal Processing and Control* [electronic article]. 2015;18:370–377. (<http://dx.doi.org/10.1016/j.bspc.2015.02.012>)
47. Muller JE. Circadian variation in cardiovascular events. *American journal of hypertension* [electronic article]. 1999;12(2 Pt 2):35S–42S. ([https://academic.oup.com/ajh/article-lookup/doi/10.1016/S0895-7061\(98\)00278-7%20http://www.sciencedirect.com/science/article/pii/S0895706198002787%20http://www.ncbi.nlm.nih.gov/pubmed/10090293](https://academic.oup.com/ajh/article-lookup/doi/10.1016/S0895-7061(98)00278-7%20http://www.sciencedirect.com/science/article/pii/S0895706198002787%20http://www.ncbi.nlm.nih.gov/pubmed/10090293))
48. Boudreau P, Dumont G, Kin NMKNY, et al. Correlation of heart rate variability and circadian markers in humans. In: *2011 annual international conference of the IEEE engineering in medicine and biology society*. IEEE; 2011:681–682. (<http://ieeexplore.ieee.org/document/6090153/>)

49. Mulcahy D, Keegan J, Crean P, et al. Silent myocardial ischaemia in chronic stable angina: A study of its frequency and characteristics in 150 patients. *Heart* [electronic article]. 1988;60(5):417–423. (<https://pmc/articles/PMC1216600/?report=abstract%20https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1216600/>)
50. Ko YA, Hayek S, Sandesara P, et al. Cohort profile: The Emory Cardiovascular Biobank (EmCAB). *BMJ Open* [electronic article]. 2017;7(12):e018753. (<http://www.ncbi.nlm.nih.gov/pubmed/29288185%20http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5778297>)
51. Shah AJ, Lampert R, Goldberg J, et al. Posttraumatic stress disorder and impaired autonomic modulation in male twins. *Biological Psychiatry* [electronic article]. 2013;73(11):1103–1110. (<http://dx.doi.org/10.1016/j.biopsych.2013.01.019>)
52. Vaccarino V, Votaw J, Faber T, et al. Major depression and coronary flow reserve detected by positron emission tomography. *Archives of Internal Medicine* [electronic article]. 2009;169(18):1668–1676. (<http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinternmed.2009.330>)
53. Goldberg J, Curran B, Vitek ME, et al. The Vietnam era twin registry. *Twin Research* [electronic article]. 2002;5(5):476–481. (<https://pubmed.ncbi.nlm.nih.gov/12537880/>)
54. Hammadah M, Al Mheid I, Wilmot K, et al. The mental stress ischemia prognosis study: Objectives, study design, and prevalence of inducible ischemia. *Psychosomatic Medicine* [electronic article]. 2017;79(3):311–317. (<http://www.ncbi.nlm.nih.gov/pubmed/28002382%20http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5373992>)
55. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability. *European Heart Journal*. 1996;17(5):354–381.
56. Vest AN, Da Poian G, Li Q, et al. An open source benchmarked toolbox for cardiovascular waveform and interval analysis. *Physiological Measurement* [electronic article]. 2018;39(10):105004. (<http://www.ncbi.nlm.nih.gov/pubmed/30199376%20http://stacks.iop.org/0967-3334/39/i=10/a=105004?key=crossref.2d9731857ae3ed429d35fce67e8ffe19>)
57. Akselrod S., Gordon D., Ubel A., et al. Power Spectrum Analysis of Heart Rate Fluctuation: A Quantitative Probe of Beat-To-Beat Cardiovascular Control. 1981.

58. Reyes del Paso GA, Langewitz W, Mulder LJM, et al. The utility of low frequency heart rate variability as an index of sympathetic cardiac tone: A review with emphasis on a reanalysis of previous studies. *Psychophysiology* [electronic article]. 2013;50(5):477–487. (<https://onlinelibrary-wiley-com.proxy.library.emory.edu/doi/pdf/10.1111/psyp.12027><http://www.ncbi.nlm.nih.gov/pubmed/23445494><http://doi.wiley.com/10.1111/psyp.12027>)
59. Bauer A, Kantelhardt JW, Barthel P, et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. *Lancet*. 2006;367(9523):1674–1681.
60. Olesen RM, Bloch Thomsen PE, Saermark K, et al. Statistical analysis of the DIAMOND MI study by the multipole method. *Physiological Measurement* [electronic article]. 2005;26(5):591–598. (<http://stacks.iop.org/0967-3334/26/i=5/a=002?key=crossref.fae68af48013829ef154a6b703ade0b3><http://www.ncbi.nlm.nih.gov/pubmed/16088054>)
61. Lewkowicz M, Levitan J, Puzanov N, et al. Description of complex time series by multipoles. *Physica A: Statistical Mechanics and its Applications*. 2002;311(1-2):260–274.
62. Refinetti R, Cornélissen G, Halberg F. Procedures for numerical analysis of circadian rhythms. *Biological Rhythm Research* [electronic article]. 2007;38(4):275–325. (<https://www.tandfonline.com/action/journalInformation?journalCode=nbr20>)
63. First M, Gibbon M. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). John Wiley & Sons, Inc.; 2004.
64. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *Journal of general internal medicine* [electronic article]. 2001;16(9):606–13. (<http://www.ncbi.nlm.nih.gov/pubmed/11556941><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1495268>)
65. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. *Clinical Psychology Review* [electronic article]. 1988;8(1):77–100. (<https://www.sciencedirect.com/science/article/pii/0272735888900505?via%3Dihub>)
66. David Goldberg A, Becker LC, Bonsall R, et al. Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress: Experience from the Psychophysiological Investigations of Myocardial Ischemia study (PIMI). *Circulation* [electronic article]. 1996;94(10):2402–2409. (<https://pubmed.ncbi.nlm.nih.gov/8921780/>)



67. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. 1983;51:606. (<http://www.ncbi.nlm.nih.gov/pubmed/6823874>)
68. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). *Journal of Clinical Investigation*. 1983;71(6):1854–1866.
69. Vaccarino V, Khan D, Votaw J, et al. Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins. *Journal of the American College of Cardiology* [electronic article]. 2011;57(11):1271–1279. (<https://pubmed.ncbi.nlm.nih.gov/21392641/>)
70. Hutchins GD, Schwaiger M, Rosenspire KC, et al. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. *Journal of the American College of Cardiology*. 1990;15(5):1032–1042.
71. Gould KL, Johnson NP. Coronary Physiology Beyond Coronary Flow Reserve in Microvascular Angina. *Journal of the American College of Cardiology* [electronic article]. 2018;72(21):2642–2662. (<https://linkinghub.elsevier.com/retrieve/pii/S0735109718386340>)
72. Shah AS. card: Cardiovascular and Autonomic Research Design. 2020;(<https://cran.r-project.org/package=card>)
73. Carlin JB, Gurrin LC, Sterne JA, et al. Regression models for twin studies: A critical review. *International Journal of Epidemiology* [electronic article]. 2005;34(5):1089–1099. (<http://academic.oup.com/ije/article/34/5/1089/645923/Regression-models-for-twin-studies-a-critical>)
74. Amorim LDAF, Cai J. Modelling recurrent events: A tutorial for analysis in epidemiology. *International Journal of Epidemiology* [electronic article]. 2015;44(1):324–333. (<https://academic.oup.com/ije/article-abstract/44/1/324/654595>)
75. Shah AS. Octomod. 2021;(<https://asshah4.github.io/octomod/>)
76. Sinnreich R, Kark JD, Friedlander Y, et al. Five minute recordings of heart rate variability for population studies: Repeatability and age-sex characteristics. *Heart* [electronic article]. 1998;80(2):156–162. (<http://heart.bmj.com/>)
77. Ahmadi N, Hajsadeghi F, Mirshkarlo HB, et al. Post-traumatic stress disorder, coronary atherosclerosis, and mortality. *American Journal of Cardiology* [electronic article]. 2011;108(1):29–33. (<https://pubmed.ncbi.nlm.nih.gov/21530936/>)

78. Salahuddin L, Cho J, Jeong MG, et al. Ultra short term analysis of heart rate variability for monitoring mental stress in mobile settings. *Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings*. 2007;4656–4659.
79. Carney RM, Saunders RD, Freedland KE, et al. Association of depression with reduced heart rate variability in coronary artery disease. *The American Journal of Cardiology*. 1995;76(8):562–564.
80. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. *Circulation* [electronic article]. 2001;104(17):2024–2028. (<http://circ.ahajournals.org/content/104/17/2024>)
81. Lam RW. Addressing circadian rhythm disturbances in depressed patients. 2008;22:13–18.
82. Iverson GL, Stampfer HG, Gaetz M. Reliability of circadian heart pattern analysis in psychiatry. *Psychiatric Quarterly*. 2002;73(3):195–203.
83. Wirz-Justice A. Diurnal variations of depressive symptoms. *Dialogues in Clinical Neuroscience*. 2008;10(3):337–343.
84. Niemeijer MN, Van Den Berg ME, Leening MJG, et al. Declining incidence of sudden cardiac death from 1990-2010 in a general middle-aged and elderly population: The Rotterdam Study. *Heart Rhythm* [electronic article]. 2015;12(1):123–129. (<https://pubmed.ncbi.nlm.nih.gov/25277989/>)
85. Madsen JK. Ischaemic heart disease and prodromes of sudden cardiac death. Is it possible to identify high risk groups for sudden cardiac death? *Br Heart J* [electronic article]. 1985;54(1):27–32. (<http://heart.bmj.com/%204015913>)
86. Hayashi M, Shimizu W, Albert CM. The Spectrum of Epidemiology Underlying Sudden Cardiac Death. *Circulation Research* [electronic article]. 2015;116(12):1887–1906. (<https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.116.304521%20http://circres.ahajournals.org>)
87. Goldenberg I, Goldkorn R, Shlomo N, et al. Heart Rate Variability for Risk Assessment of Myocardial Ischemia in Patients Without Known Coronary Artery Disease: The HRV-DETECT (Heart Rate Variability for the Detection of Myocardial Ischemia) Study. *Journal of the American Heart Association* [electronic article]. 2019;8(24):e014540. (<https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.014540>)
88. Lown B. Sudden cardiac death – 1978. *Circulation* [electronic article]. 1979;60(7):1593–1599. (<http://circ.ahajournals.org/%20https://www.ahajournals.org/doi/10.1161/01.CIR.60.7.1593>)



89. Hammadah M, Kim JH, Al Mheid I, et al. Coronary and peripheral vasomotor responses to mental stress. *Journal of the American Heart Association* [electronic article]. 2018;7(10). (<http://jaha.ahajournals.org/content/7/10/e008532/DC1/embed/inline-supplementary->)
90. Maheshwari A, Norby FL, Soliman EZ, et al. Low heart rate variability in a 2-minute electrocardiogram recording is associated with an increased Risk of sudden cardiac death in the general population: The Atherosclerosis Risk in communities study. *PLoS ONE* [electronic article]. 2016;11(8). (<http://www2.csc.unc.edu/>)
91. Deyell MW, Krahn AD, Goldberger JJ. Sudden Cardiac Death Risk Stratification. *Circulation Research* [electronic article]. 2015;116(12):1907–1918. (<https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.116.304493>)
92. Bauer A. Identifying high-risk post-infarction patients by autonomic testing — Below the tip of the iceberg. *International Journal of Cardiology* [electronic article]. 2017;237:19–21. (<http://dx.doi.org/10.1016/j.ijcard.2017.03.087>)
93. Shivkumar K, Ajijola OA, Anand I, et al. Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. *Journal of Physiology* [electronic article]. 2016;594(14):3911–3954. (<https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/JP271870><https://physoc.onlinelibrary.wiley.com/doi/abs/10.1113/JP271870><https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP271870>)
94. Nunan D, Sandercock GRH, Brodie DA. A quantitative systematic review of normal values for short-term heart rate variability in healthy adults. 2010;33:1407–1417. (<https://pubmed.ncbi.nlm.nih.gov/20663071/>)
95. Blase KL, Dijke A van, Cluitmans PJM, et al. Efficacy of HRV-biofeedback as additional treatment of depression and PTSD. *The American Journal of Psychiatry* [electronic article]. 2010;58(4):292–300. (<http://www.ncbi.nlm.nih.gov/pubmed/27075221>)

# APPENDIX


## A TABLES AND FIGURES

### A.1 Clinical Overview

*The follow section divides the relevant figures and tables into those describing the study, aims, and clinical cohorts.*

## A.1.1 Overview of Stress Reactivity

## Stress Reactivity and the Neurocardiac Axis



Directed acyclic graph of the relationship of the specific aims of this study. It demonstrates the relationship between autonomic dysfunction on ischemic heart disease, psychological distress, and future cardiovascular events.

## A.1.2 Biobank Cohort Description

Emory Cardiovascular Biobank Cohort Description	
Characteristic	N = 56 <sup>1</sup>
Age (years)	62 (52, 70)
Race	
African American Black	14 (26%)
Asian	2 (3.8%)
Caucasian White	37 (70%)
BMI (kg/m <sup>2</sup> )	29.3 (26.2, 34.0)
Sex	
Female	9 (17%)
Male	44 (83%)
Setting	
Inpatient	20 (36%)
Outpatient	36 (64%)
Reason for Catheterization	
Heart Failure	9 (16%)
Heart Transplant	6 (11%)
Other	7 (12%)
Preoperative Risk	6 (11%)
Stress Test	8 (14%)
UA/NSTEMI	20 (36%)
PHQ-9 Score	4.5 (1.0, 9.0)
Depression	10 (21%)
Gensini Score	26 (20, 51)
Stenosis	34 (71%)
CASS-70 Score	
0	21 (44%)
1	13 (27%)
2	9 (19%)
3	5 (10%)

<sup>1</sup>Median (IQR); n (%)

A description of subjects undergoing left heart catheterization with coronary angiography, including burden of coronary artery disease. CASS = Coronary Artery Surgery Score, PHQ = Patient Health Questionnaire, BMI = Body Mass Index.

### A.1.3 Twin Cohorts Description

Emory Twins Study Cohort Discription				
Characteristic	THS1, N = 361 <sup>1</sup>	SAVEIT, N = 206 <sup>1</sup>	THS2, N = 165 <sup>1</sup>	ETSF, N = 280 <sup>1</sup>
Age (years)	55.0 (52.0, 57.0)	57.0 (56.0, 59.0)	61.0 (59.0, 62.0)	68.4 (66.8, 69.5)
BMI (kg/m <sup>2</sup> )	28.0 (26.0, 32.0)	30.0 (27.0, 33.0)	30.0 (27.0, 33.0)	29.0 (27.0, 32.0)
Race				
White	345 (96%)	198 (96%)	157 (95%)	269 (96%)
African American	12 (3.3%)	8 (3.9%)	6 (3.6%)	7 (2.5%)
Asian	4 (1.1%)	0 (0%)	2 (1.2%)	4 (1.4%)
Current Smoker	230 (64%)	155 (76%)	120 (74%)	178 (64%)
Known IHD	34 (9.4%)	30 (15%)	29 (18%)	11 (3.9%)
Congestive Heart Failure	2 (0.6%)	0 (0%)	3 (1.8%)	4 (1.4%)
Hypertension	106 (29%)	69 (33%)	91 (55%)	165 (59%)
Diabetes Mellitus	33 (9.1%)	34 (17%)	27 (16%)	64 (23%)
Post-Traumatic Stress Disorder	22 (6.1%)	59 (29%)	45 (27%)	41 (15%)
Depression	40 (11%)	42 (20%)	26 (16%)	27 (9.7%)
Abnormal Myocardial Perfusion	40 (13%)	10 (5.9%)	29 (18%)	32 (12%)

<sup>1</sup>Median (IQR); n (%)

Description of the veteran twin subjects within each follow-up period. They were evaluated for clinical characteristics, including quantitative myocardial perfusion imaging. THS = Twins Heart Study, SAVEIT = Stress and Vascular Evaluation in Twins, ETFS = Emory Twins Study Follow-Up.

### A.1.4 Mental Stress Cohorts Description

MIMS and MIPS Cohort Discription				
Characteristic	MIMS		MIPS	
	MSIMI = 0, N = 256 <sup>1</sup>	MSIMI = 1, N = 50 <sup>1</sup>	MSIMI = 0, N = 440 <sup>1</sup>	MSIMI = 1, N = 188 <sup>1</sup>
Age (years)	52.0 (47.0, 56.2)	51.5 (46.6, 54.7)	66 (58, 71)	64 (57, 71)
Sex (Female)	117 (46%)	33 (66%)	92 (21%)	76 (40%)
Race				
White	79 (31%)	9 (18%)	308 (70%)	115 (61%)
Black	165 (64%)	36 (72%)	110 (25%)	67 (36%)
Other	12 (4.7%)	5 (10%)	22 (5.0%)	6 (3.2%)
BMI (kg/m <sup>2</sup> )	30 (26, 35)	30 (26, 38)	29.1 (25.6, 32.1)	29.5 (26.2, 32.8)
Current Smoker	62 (25%)	11 (22%)	215 (49%)	84 (45%)
Obstructive Coronary Artery Disease	201 (84%)	41 (89%)	316 (83%)	132 (85%)
Diabetes Mellitus	79 (31%)	18 (36%)	137 (31%)	69 (37%)
Coronary Artery Bypass Graft	51 (20%)	12 (24%)	139 (32%)	75 (40%)
Percutaneous Coronary Intervention	177 (69%)	35 (70%)	226 (51%)	100 (53%)
Hyperlipidemia	206 (80%)	40 (80%)	369 (84%)	151 (80%)
Hypertension	205 (80%)	42 (84%)	325 (74%)	147 (78%)
PSIMI	49 (20%)	20 (40%)	121 (28%)	96 (53%)
Depression	92 (37%)	16 (32%)	111 (26%)	51 (28%)
Post-Traumatic Stress Disorder	32 (13%)	12 (24%)	35 (8.2%)	8 (4.4%)

<sup>1</sup>Median (IQR); n (%)

These cohorts had different levels of cardiovascular risk prior to enrollment. MIPS had myocardial infarction as an inclusion criteria. In addition, there was some cross-over between studies. MSIMI = Mental Stress Induced Myocardial Ischemia; PSIMI = Physical Stress Induced Myocardial Ischemia, MIMS = Myocardial Infarction and Mental Stress, MIPS = Mental Stress Ischemia Mechanisms and Prognosis Study

## A.1.5 HRV in Twins Cohorts

Description of HRV Emory Twins Study				
ECG/HRV Metric	THS1, N = 361 <sup>1</sup>	SAVEIT, N = 206 <sup>1</sup>	THS2, N = 165 <sup>1</sup>	ETSF, N = 280 <sup>1</sup>
RR Interval	0.05 (-0.59, 0.68)	-0.25 (-0.85, 0.40)	0.08 (-0.52, 0.72)	0.03 (-0.65, 0.69)
SDNN	0.18 (-0.28, 0.66)	-0.08 (-0.48, 0.45)	-0.05 (-0.47, 0.45)	-0.21 (-0.59, 0.26)
RMSSD	-0.06 (-0.43, 0.42)	-0.23 (-0.62, 0.31)	-0.17 (-0.57, 0.42)	-0.18 (-0.58, 0.52)
PNN50	-0.18 (-0.49, 0.41)	-0.35 (-0.59, 0.22)	-0.31 (-0.59, 0.35)	-0.36 (-0.59, 0.26)
Ultra Low Frequency	0.14 (-0.21, 0.46)	0.07 (-0.27, 0.41)	0.10 (-0.27, 0.40)	-0.07 (-0.41, 0.23)
Very Low Frequency	0.28 (-0.17, 0.66)	0.09 (-0.36, 0.53)	0.08 (-0.38, 0.49)	-0.11 (-0.54, 0.30)
Low Frequency	0.36 (-0.11, 0.81)	0.18 (-0.37, 0.67)	0.06 (-0.53, 0.54)	-0.16 (-0.66, 0.41)
High Frequency	0.21 (-0.29, 0.66)	0.04 (-0.55, 0.58)	0.04 (-0.56, 0.68)	-0.03 (-0.62, 0.70)
Low/High Frequency Ratio	-0.05 (-0.41, 0.43)	-0.07 (-0.45, 0.40)	-0.27 (-0.57, 0.21)	-0.32 (-0.64, 0.13)
Total Power	0.31 (-0.15, 0.71)	0.11 (-0.37, 0.57)	0.10 (-0.42, 0.52)	-0.11 (-0.58, 0.34)
Acceleration Capacity	-0.22 (-0.84, 0.39)	0.07 (-0.53, 0.59)	0.09 (-0.46, 0.63)	0.35 (-0.34, 0.75)
Deceleration Capacity	0.22 (-0.40, 0.85)	-0.05 (-0.59, 0.52)	-0.11 (-0.62, 0.45)	-0.34 (-0.75, 0.32)
Sample Entropy	NA (NA, NA)	NA (NA, NA)	NA (NA, NA)	NA (NA, NA)
Approximate Entropy	-0.11 (-0.40, 0.26)	-0.01 (-0.34, 0.36)	-0.08 (-0.40, 0.29)	0.06 (-0.29, 0.46)
Dyx	0.08 (-0.59, 0.77)	-0.06 (-0.67, 0.60)	-0.05 (-0.68, 0.61)	-0.33 (-1.01, 0.35)

<sup>1</sup>Median (IQR)


Heart rate variability is described in each of the follow-up periods. HRV = heart rate variability, Dyx = kurtosis of Poincare plot, SDNN = the standard deviation of normally conducted RR intervals, RMSSD = the root mean square of successive differences in normally conducted RR intervals, PNN50 = proportion of normally conducted RR intervals that differ by more than 50 ms divided by the total number of normally conducted RR intervals



## A.2 Psychological Stress

*The follow section divides the relevant figures and tables into those that pertain to the relationship of autonomic function and psychological stress, including both acute mental stress and chronic psychological stress.*

## A.2.1 HRV and Mental Stress Challenge



This describes the distribution of ECG metrics during each phase of the acute mental stress challenge. The units of each correspond to the original metric.

### A.2.2 Distribution of HRV and Mental Stress Challenge

Mental Stress Challenge Phases and ECG Metrics  
MIMS/MIPS Cohorts

	Mean (95% CI)	T-statistic
Heart Rate		
Stress	0.00 (−0.06, 0.07)	0.12
Recovery	−0.00 (−0.05, 0.05)	−0.07
High Frequency HRV		
Stress	−0.00 (−0.06, 0.05)	−0.04
Recovery	−0.01 (−0.05, 0.04)	−0.31
Low Frequency HRV		
Stress	0.00 (−0.06, 0.06)	0.07
Recovery	0.00 (−0.05, 0.05)	0.00
T Wave Area		
Stress	−0.00 (−0.09, 0.08)	−0.03
Recovery	−0.00 (−0.07, 0.07)	−0.01

HRV summarised during stress and recovery phase of the mental stress challenge were compared to rest HRV. HRV = heart rate variability.

### A.2.3 Depression and PTSD with Mental Stress Challenge

Mental Stress Challenge HRV and Chronic Psychological Stress  
MIMS/MIPS Cohorts

ECG/HRV Metric	Depression <sup>1</sup>	PTSD <sup>1</sup>
Heart Rate		
Rest	1.19 (1.02, 1.39)	1.43 (1.14, 1.78)
Stress	1.01 (0.86, 1.19)	1.06 (0.83, 1.33)
Recovery	1.12 (0.96, 1.31)	1.2 (0.95, 1.5)
T Wave Area		
Rest	1.01 (0.83, 1.17)	1.07 (0.84, 1.25)
Stress	1.11 (0.95, 1.3)	1.17 (0.96, 1.42)
Recovery	1.16 (1, 1.37)	1.23 (1.03, 1.48)
High Frequency HRV		
Rest	1 (0.85, 1.17)	0.85 (0.69, 1.07)
Stress	0.92 (0.79, 1.07)	0.85 (0.68, 1.06)
Recovery	0.89 (0.77, 1.05)	0.81 (0.66, 1.01)
Low Frequency HRV		
Rest	0.9 (0.77, 1.05)	0.85 (0.69, 1.06)
Stress	0.91 (0.78, 1.06)	0.86 (0.71, 1.08)
Recovery	0.81 (0.69, 0.95)	0.82 (0.67, 1.02)

<sup>1</sup>Logistic regression model, OR with 95% CI and concordance statistic.

The association between HRV during mental stress challenge and the chronic psychological stressors of depression and PTSD are described. HRV = heart rate variability.

### A.2.4 Depression by PHQ-9 and HRV

HRV and Depression by PHQ-9  
Emory Cardiovascular Biobank

HRV Metric	No Depression, N = 38 <sup>1</sup>	Depression, N = 10 <sup>1</sup>	p-value <sup>2</sup>
RR Interval	0.40 (-0.31, 0.71)	-0.37 (-0.58, 0.66)	0.6
SDNN	0.12 (-0.41, 0.66)	-0.24 (-0.56, 0.34)	0.6
RMSSD	-0.16 (-0.34, 0.18)	-0.41 (-0.52, -0.14)	0.13
PNN50	-0.27 (-0.38, 0.07)	-0.40 (-0.43, -0.23)	0.089
Ultra Low Frequency	0.35 (0.10, 0.60)	0.20 (-0.15, 0.62)	0.7
Very Low Frequency	0.42 (0.08, 0.82)	0.19 (-0.16, 0.71)	0.8
Low Frequency	0.41 (-0.01, 0.82)	0.03 (-0.46, 0.78)	0.5
High Frequency	0.14 (-0.19, 0.75)	-0.35 (-0.68, 0.22)	0.12
Low/High Frequency Ratio	0.02 (-0.36, 0.32)	-0.02 (-0.16, 0.36)	0.9
Total Power	0.47 (-0.06, 0.83)	0.07 (-0.45, 0.67)	0.7
Acceleration Capacity	-0.11 (-0.78, 0.31)	0.37 (-0.27, 0.59)	0.3
Deceleration Capacity	-0.05 (-0.29, 0.68)	-0.29 (-0.47, 0.39)	0.4
Sample Entropy	0.30 (-0.25, 0.71)	0.15 (-0.38, 0.48)	0.4
Approximate Entropy	-0.10 (-0.43, 0.46)	0.23 (-0.02, 0.48)	0.4
Dyx	1.75 (1.29, 2.57)	2.07 (1.76, 2.69)	0.4

<sup>1</sup>Median (IQR)

<sup>2</sup>Wilcoxon rank sum exact test

In patients undergoing angiography, HRV metrics were described in those with moderate to severe depressive symptoms to those with mild to minimal symptoms by PHQ-9. HRV = Heart Rate Variability, PHQ-9 = Patient Health Questionnaire.

### A.2.5 HRV and Chronic Mental Stress in Twins

Morning HRV and Chronic Psychological Stress Emory Twins Study					
	AC	<i>Dyx</i>	HF	LF	VLF
PTSD					
Model 1	1.81 (1.06, 3.09)	0.87 (0.44, 1.71)	0.61 (0.40, 0.92)	0.55 (0.35, 0.87)	0.61 (0.37, 1.01)
Model 2	1.66 (1.09, 2.53)	2.30 (1.00, 5.30)	0.67 (0.67, 0.67)	0.48 (0.48, 0.48)	0.66 (0.41, 1.07)
Model 3	1.96 (1.27, 3.02)	2.18 (0.57, 8.31)	0.54 (0.37, 0.78)	0.49 (0.32, 0.76)	0.71 (0.43, 1.16)
Depression					
Model 1	2.58 (1.51, 4.41)	0.66 (0.32, 1.37)	0.35 (0.08, 1.49)	0.42 (0.42, 0.42)	0.18 (0.09, 0.37)
Model 2	6.20 (0.33, 116.72)	0.80 (0.80, 0.80)	0.44 (0.28, 0.70)	0.26 (0.16, 0.43)	0.00 (0.00, 0.07)
Model 3	9.33 (0.19, 468.26)	1.06 (1.06, 1.06)	0.04 (0.00, 0.75)	0.23 (0.14, 0.40)	0.18 (0.09, 0.36)

<sup>1</sup>Model 1 = HRV

<sup>2</sup>Model 2 = Model 1 + Age + BMI + Race

<sup>3</sup>Model 3 = Model 2 + Smoking + HTN + Cardiovascular Disease

Depression is measured as a binary outcome with Beck Depression Inventory score > 14. The HRV was selected at approximately 7 AM. PTSD = Post-Traumatic Stress Disorder, HRV = heart rate variability, LF = low frequency HRV, HF = high frequency HRV, VLF = very low frequency HRV, AC = acceleration capacity

### A.2.6 Circadian Autonomic Variability and Chronic Mental Stress

Circadian HRV and Chronic Psychological Stress  
Emory Twins Study

	MESOR	Amplitude	Phi
PTSD			
High Frequency HRV	0.54 (0.35, 0.81)	0.24 (0.07, 0.81)	1.12 (0.95, 1.33)
Low Frequency HRV	0.46 (0.3, 0.69)	0.33 (0.15, 0.75)	0.95 (0.8, 1.13)
Very Low Frequency HRV	0.49 (0.29, 0.84)	0.44 (0.23, 0.84)	1.16 (0.91, 1.47)
Acceleration Capacity	1.88 (1.17, 3.02)	0.24 (0.08, 0.72)	0.87 (0.71, 1.08)
Dyx	0.72 (0.54, 0.96)	0.94 (0.64, 1.4)	1.16 (0.94, 1.44)
Depression			
High Frequency HRV	0.38 (0.22, 0.64)	0.35 (0.15, 0.82)	1.14 (0.93, 1.4)
Low Frequency HRV	0.25 (0.14, 0.45)	0.29 (0.13, 0.66)	1.04 (0.84, 1.3)
Very Low Frequency HRV	0.19 (0.09, 0.4)	0.21 (0.09, 0.45)	1.22 (0.89, 1.67)
Acceleration Capacity	3.08 (1.71, 5.54)	0.31 (0.13, 0.75)	0.94 (0.73, 1.21)
Dyx	0.43 (0.31, 0.61)	0.67 (0.41, 1.09)	0.95 (0.75, 1.21)

Depression is measured as a binary outcome with Beck Depression Inventory score  $> 14$ . The HRV metrics are measured over 24 hours using cosinor statistics. PTSD = Post-Traumatic Stress Disorder, HRV = heart rate variability, LF = low frequency HRV, HF = high frequency HRV, VLF = very low frequency HRV, AC = acceleration capacity, MESOR = midline estimating statistic of rhythm, Amplitude = maximum distance from MESOR, Phi = shift of acrophase

### A.3 Myocardial Ischemia

*The follow section divides the relevant figures and tables into those that pertain to the relationship of autonomic function and myocardial ischemia, including both obstructive coronary artery disease and myocardial perfusion.*



### A.3.1 Relationship Between Obstructive and Non-Obstructive Coronary Artery Disease

HRV and Obstructive CAD Emory Cardiovascular Biobank			
Characteristic	Nonobstructive CAD, N = 22 <sup>1</sup>	Obstructive CAD, N = 34 <sup>1</sup>	p-value <sup>2</sup>
RR Interval	-0.56 (-0.91, 0.51)	0.38 (-0.11, 0.72)	0.086
SDNN	-0.41 (-0.54, 0.74)	0.12 (-0.25, 0.59)	0.3
RMSSD	-0.31 (-0.47, 0.23)	-0.08 (-0.32, 0.28)	0.4
PNN50	-0.35 (-0.42, 0.20)	-0.16 (-0.38, 0.12)	0.4
Ultra Low Frequency	0.12 (-0.04, 0.71)	0.34 (0.20, 0.55)	0.7
Very Low Frequency	0.08 (-0.26, 0.90)	0.47 (0.18, 0.75)	0.5
Low Frequency	-0.01 (-0.61, 1.11)	0.55 (0.09, 0.79)	0.6
High Frequency	-0.10 (-0.35, 0.87)	0.18 (-0.13, 0.77)	0.7
Low/High Frequency Ratio	-0.19 (-0.37, -0.06)	0.08 (-0.36, 0.38)	0.12
Total Power	-0.06 (-0.45, 0.97)	0.47 (0.05, 0.80)	0.7
Acceleration Capacity	0.22 (-0.82, 0.45)	-0.11 (-0.63, 0.34)	0.7
Deceleration Capacity	-0.12 (-0.42, 1.06)	-0.08 (-0.29, 0.60)	>0.9
Sample Entropy	0.20 (-0.31, 0.45)	0.21 (-0.20, 0.59)	0.6
Approximate Entropy	-0.03 (-0.43, 0.84)	-0.10 (-0.41, 0.29)	0.4
Dyx	1.69 (1.19, 1.78)	2.03 (1.52, 2.71)	0.081

<sup>1</sup>Median (IQR)

<sup>2</sup>Wilcoxon rank sum exact test

In patients undergoing angiography, HRV metrics were described in those with both obstructive (>70%) and nonobstructive CAD, and evaluated for differences in distribution. HRV = Heart Rate Variability, CAD = Coronary Artery Disease.

### A.3.2 Effective of Revascularization on Autonomic Function

HRV and Revascularization Emory Cardiovascular Biobank			
Characteristic	No Revascularization, N = 34 <sup>1</sup>	Revascularization, N = 22 <sup>1</sup>	p-value <sup>2</sup>
RR Interval	0.01 (-0.69, 0.48)	0.59 (-0.06, 0.81)	0.065
SDNN	0.04 (-0.51, 0.56)	0.08 (-0.22, 0.82)	0.3
RMSSD	-0.03 (-0.44, 0.23)	-0.22 (-0.34, 0.34)	0.8
PNN50	-0.22 (-0.39, 0.15)	-0.27 (-0.40, 0.05)	>0.9
Ultra Low Frequency	0.20 (-0.04, 0.66)	0.35 (0.21, 0.55)	0.4
Very Low Frequency	0.34 (-0.26, 0.83)	0.42 (0.21, 0.71)	0.5
Low Frequency	0.39 (-0.27, 1.01)	0.41 (0.09, 0.78)	0.7
High Frequency	0.38 (-0.25, 0.79)	-0.01 (-0.17, 0.72)	>0.9
Low/High Frequency Ratio	-0.12 (-0.49, 0.28)	0.06 (-0.18, 0.42)	0.2
Total Power	0.35 (-0.27, 0.91)	0.33 (0.06, 0.81)	0.6
Acceleration Capacity	0.03 (-0.81, 0.37)	0.03 (-0.48, 0.34)	>0.9
Deceleration Capacity	-0.12 (-0.30, 0.85)	-0.08 (-0.32, 0.37)	>0.9
Sample Entropy	0.06 (-0.42, 0.45)	0.42 (-0.05, 0.59)	0.3
Approximate Entropy	-0.18 (-0.46, 0.30)	-0.03 (-0.34, 0.46)	0.6
Dyx	1.72 (1.27, 2.15)	2.27 (1.61, 2.82)	0.15

<sup>1</sup>Median (IQR)

<sup>2</sup>Wilcoxon rank sum exact test

In patients undergoing angiography, HRV metrics were described in those that received revascularization, and evaluated for differences in distribution. Of note, not all obstructive CAD was amenable to revascularization, based on location of lesion. Only those that underwent intervention, either angioplasty or stent placement, were considered to be revascularized. HRV = Heart Rate Variability, CAD = Coronary Artery Disease.

### A.3.3 HRV by Timing of Revascularization

HRV and Timing of Myocardial Reperfusion  
Emory Cardiovascular Biobank

Characteristic	No Revascularization			Revascularization		
	Angiography, N = 13 <sup>1</sup>	Before, N = 14 <sup>1</sup>	p-value <sup>2</sup>	Balloon, N = 10 <sup>1</sup>	Before, N = 13 <sup>1</sup>	p-value <sup>2</sup>
RR Interval	-0.3 (-0.6, 0.5)	0.2 (-0.4, 0.8)	0.3	0.6 (0.0, 0.8)	0.5 (0.1, 0.6)	0.7
SDNN	0.4 (-0.4, 0.9)	0.3 (-0.4, 0.5)	0.8	-0.1 (-0.4, 0.9)	-0.1 (-0.2, 0.1)	>0.9
RMSSD	0.4 (-0.5, 0.6)	-0.1 (-0.3, 0.2)	0.8	-0.3 (-0.4, -0.1)	-0.3 (-0.5, -0.1)	>0.9
Ultra Low Frequency	0.6 (0.3, 1.0)	0.4 (0.1, 0.6)	0.5	0.6 (0.4, 0.9)	0.4 (0.1, 1.0)	0.7
Very Low Frequency	0.8 (0.2, 1.0)	0.6 (-0.1, 0.9)	0.5	0.4 (0.2, 0.7)	0.4 (0.2, 0.7)	>0.9
Low Frequency	0.7 (0.0, 1.2)	0.7 (-0.1, 1.0)	0.8	0.5 (-0.1, 0.9)	0.4 (0.0, 0.9)	>0.9
High Frequency	1.0 (0.0, 1.1)	0.2 (0.0, 0.7)	0.5	-0.2 (-0.4, 0.4)	0.1 (-0.5, 0.4)	>0.9
Low/High Frequency Ratio	-0.3 (-0.5, -0.1)	0.0 (-0.5, 0.5)	0.3	-0.1 (-0.4, 0.9)	-0.2 (-0.2, 0.9)	0.8
Total Power	0.7 (0.1, 1.1)	0.7 (-0.1, 0.9)	0.6	0.3 (0.0, 1.0)	0.4 (0.2, 0.6)	>0.9
Acceleration Capacity	-0.2 (-0.4, 0.4)	-0.3 (-0.8, 0.4)	0.7	0.3 (-0.6, 0.4)	0.1 (-0.5, 0.4)	0.9
Deceleration Capacity	0.0 (-0.3, 0.6)	0.3 (-0.4, 0.9)	0.8	-0.2 (-0.4, 0.4)	-0.1 (-0.3, 0.3)	>0.9
Sample Entropy	-0.5 (-0.6, 0.3)	0.1 (-0.4, 0.7)	0.3	0.1 (-0.6, 0.2)	0.2 (0.0, 0.5)	0.3
Approximate Entropy	-0.5 (-1.3, -0.1)	-0.4 (-0.9, 0.1)	0.9	-0.1 (-0.4, 0.3)	0.0 (-0.7, 0.3)	>0.9

<sup>1</sup>Median (IQR)

<sup>2</sup>Wilcoxon rank sum exact test

HRV was measured before the procedure started and during the time of coronary angiography (versus intervention). Coronary arteries with obstructive disease are reperfused using balloon angioplasty and potential stenting. HRV = Heart Rate Variability, CAD = Coronary Artery Disease.

### A.3.4 Relationship of HRV with both Mental and Physical Stress

Myocardial Perfusion Imaging with Physical and Mental Stress MIMS/MIPS Cohorts			
ECG/HRV Metric	Combined MSIMI/PSIMI <sup>1</sup>	MSIMI <sup>1</sup>	PSIMI <sup>1</sup>
Heart Rate			
Rest	1.04 (0.9, 1.21)	1.2 (1.01, 1.41)	0.96 (0.82, 1.12)
Stress	1 (0.86, 1.15)	1.12 (0.95, 1.32)	1.03 (0.88, 1.21)
Recovery	0.98 (0.84, 1.13)	1.11 (0.94, 1.31)	0.93 (0.79, 1.09)
T Wave Area			
Rest	0.96 (0.78, 1.11)	0.88 (0.57, 1.09)	0.96 (0.74, 1.12)
Stress	1.02 (0.88, 1.18)	0.96 (0.8, 1.14)	1.09 (0.93, 1.26)
Recovery	0.99 (0.85, 1.15)	0.81 (0.64, 1)	1.03 (0.88, 1.2)
High Frequency HRV			
Rest	0.9 (0.78, 1.04)	0.84 (0.71, 0.98)	0.9 (0.77, 1.05)
Stress	0.88 (0.76, 1.02)	0.77 (0.65, 0.9)	0.94 (0.81, 1.1)
Recovery	0.94 (0.81, 1.08)	0.86 (0.73, 1.01)	0.95 (0.81, 1.11)
Low Frequency HRV			
Rest	0.89 (0.76, 1.03)	0.83 (0.7, 0.97)	0.87 (0.74, 1.02)
Stress	0.87 (0.74, 1)	0.77 (0.66, 0.91)	0.86 (0.74, 1.01)
Recovery	0.87 (0.75, 1.01)	0.78 (0.66, 0.91)	0.88 (0.75, 1.02)

<sup>1</sup>Logistic regression model, OR with 95% CI and concordance statistic.

HRV was measured during the three stages of mental stress challenge and compared in logistic regression models with the results of myocardial perfusion imaging. HRV = heart rate variability, MSIMI = mental stress-induced myocardial ischemia, PSIMI = physical stress-induced myocardial ischemia, AUC = area under receiver-operator curve. Bolded text signifies a p-value < 0.05.

### A.3.5 Quantitative Myocardial Perfusion and HRV

Myocardial Perfusion Imaging and Morning HRV  
Emory Twins Study

	AC	<i>Dyx</i>	HF	LF	VLF
Coronary Flow Reserve					
Model 1	0.83 (0.76, 0.92)	1.10 (1.04, 1.17)	1.11 (1.02, 1.22)	1.22 (1.11, 1.35)	1.21 (1.07, 1.36)
Model 2	0.84 (0.76, 0.93)	1.07 (1.01, 1.14)	1.12 (1.02, 1.23)	1.21 (1.09, 1.34)	1.19 (1.05, 1.34)
Model 3	0.87 (0.79, 0.96)	1.03 (0.97, 1.10)	1.11 (1.01, 1.21)	1.15 (1.03, 1.28)	1.13 (0.99, 1.28)
Abnormal MPI					
Model 1	0.82 (0.57, 1.18)	0.77 (0.60, 0.99)	1.24 (0.87, 1.77)	2.48 (0.33, 18.44)	0.81 (0.49, 1.35)
Model 2	0.83 (0.58, 1.20)	0.76 (0.59, 0.98)	1.23 (0.86, 1.77)	0.94 (0.62, 1.44)	0.80 (0.47, 1.34)
Model 3	0.76 (0.49, 1.16)	0.75 (0.58, 0.98)	1.28 (0.86, 1.89)	0.98 (0.63, 1.53)	0.84 (0.48, 1.45)

<sup>1</sup>Model 1 = HRV

<sup>2</sup>Model 2 = Model 1 + Age + BMI + Race

<sup>3</sup>Model 3 = Model 2 + Smoking + HTN + Cardiovascular Disease

Relationship between abnormal MPI and CFR with HRV. HRV was measured at 7 AM. HRV = heart rate variability, MPI = myocardial perfusion imaging, CFR = coronary flow reserve, LF = low frequency HRV, HF = high frequency HRV, VLF = very low frequency HRV, AC = acceleration capacity

### A.3.6 Circadian HRV and Myocardial Perfusion

Circadian HRV and Myocardial Perfusion Abnormalities Emory Twins Study			
	MESOR	Amplitude	Phi
Coronary Flow Reserve			
High Frequency HRV	1.12 (1.02, 1.24)	1.12 (0.99, 1.27)	0.99 (0.95, 1.04)
Low Frequency HRV	1.22 (1.1, 1.35)	1.15 (0.97, 1.36)	1.01 (0.96, 1.05)
Very Low Frequency HRV	1.1 (0.99, 1.22)	1.1 (0.98, 1.22)	1 (0.93, 1.07)
Acceleration Capacity	0.85 (0.77, 0.93)	1.06 (0.9, 1.24)	1.03 (0.97, 1.08)
Dyx	1.15 (1.07, 1.24)	1.11 (1, 1.23)	0.98 (0.92, 1.04)
Abnormal MPI			
High Frequency HRV	1.35 (0.89, 2.05)	1.95 (0.96, 3.95)	1.03 (0.85, 1.24)
Low Frequency HRV	0.89 (0.58, 1.36)	1.16 (0.61, 2.2)	0.94 (0.77, 1.14)
Very Low Frequency HRV	0.85 (0.53, 1.37)	0.99 (0.59, 1.65)	0.86 (0.66, 1.12)
Acceleration Capacity	0.89 (0.62, 1.29)	1.92 (1.06, 3.48)	0.89 (0.7, 1.15)
Dyx	0.91 (0.67, 1.24)	0.81 (0.48, 1.38)	0.88 (0.7, 1.09)

Myocardial perfusion was quantified as a continuous variable and as a binary of abnormal or normal. The HRV metrics are measured over 24 hours using cosinor statistics. MPI = myocardial perfusion imaging, CFR = coronary flow reserve, HRV = heart rate variability, LF = low frequency HRV, HF = high frequency HRV, VLF = very low frequency HRV, AC = acceleration capacity, MESOR = midline estimating statistic of rhythm, Amplitude = maximum distance from MESOR, Phi = shift of acrophase

### A.3.7 Distribution of HRV and MSIMI

HRV distribution by MSIMI MIMS/MIPS cohorts			
Characteristic	MSIMI = 0, N = 710 <sup>1</sup>	MSIMI = 1, N = 243 <sup>1</sup>	p-value <sup>2</sup>
Heart Rate			
Rest	-0.08 (-0.72, 0.56)	-0.08 (-0.50, 0.80)	0.090
Stress	-0.11 (-0.73, 0.58)	0.03 (-0.59, 0.72)	0.092
Recovery	-0.09 (-0.64, 0.47)	-0.12 (-0.64, 0.77)	0.5
T Wave Area			
Rest	-0.14 (-0.26, 0.08)	-0.14 (-0.26, 0.08)	0.8
Stress	-0.22 (-0.56, 0.20)	-0.22 (-0.56, 0.28)	0.9
Recovery	-0.16 (-0.55, 0.22)	-0.32 (-0.63, 0.15)	0.024
High Frequency HRV			
Rest	0.18 (-0.36, 0.70)	0.04 (-0.65, 0.54)	0.017
Stress	0.24 (-0.39, 0.70)	-0.01 (-0.73, 0.46)	<0.001
Recovery	0.21 (-0.38, 0.69)	-0.02 (-0.64, 0.57)	0.034
Low Frequency HRV			
Rest	0.16 (-0.36, 0.60)	-0.04 (-0.74, 0.49)	0.010
Stress	0.19 (-0.30, 0.59)	-0.06 (-0.63, 0.40)	<0.001
Recovery	0.22 (-0.37, 0.63)	-0.03 (-0.67, 0.41)	<0.001

<sup>1</sup>Median (IQR)

<sup>2</sup>Wilcoxon rank sum test

The distribution of HRV between those with MSIMI and those without. The HRV metric are stratified by phase of mental stress challenge. MSIMI = mental stress-induced myocardial ischemia, HRV = heart rate variability.

### A.3.8 Modeling Mental Stress-Induced Myocardial Ischemia and HRV

Mental Stress-Induced Myocardial Ischemia and HRV  
MIMS/MIPS Cohorts

Sequential Models	Stress LF	Rest LF	Stress HF	Rest HF
Model 1	0.77 (0.66, 0.91)	0.83 (0.7, 0.97)	0.77 (0.65, 0.9)	0.84 (0.71, 0.98)
Model 2	0.79 (0.67, 0.94)	0.85 (0.72, 1.01)	0.75 (0.63, 0.89)	0.8 (0.68, 0.95)
Model 3	0.81 (0.68, 0.96)	0.87 (0.73, 1.04)	0.76 (0.64, 0.91)	0.82 (0.69, 0.98)
Model 4	0.82 (0.68, 0.97)	0.88 (0.74, 1.04)	0.77 (0.65, 0.92)	0.83 (0.69, 0.99)
Model 5	0.81 (0.68, 0.97)	0.88 (0.74, 1.05)	0.76 (0.64, 0.91)	0.82 (0.69, 0.99)

<sup>1</sup>Model 1 = MSIMI ~ HRV

<sup>2</sup>Model 2 = Model 1 + Age + BMI + Sex + Race

<sup>3</sup>Model 3 = Model 2 + Smoking + Diabetes + Hypertension + Hyperlipidemia

<sup>4</sup>Model 4 = Model 3 + Known Coronary/Peripheral Artery Disease

<sup>5</sup>Model 5 = Model 4 + Depression + Post-Traumatic Stress Disorder

The association between the exposure of HRV with the finding of MSIMI is described. The HRV metric are stratified by phase of mental stress challenge. MSIMI = mental stress-induced myocardial ischemia, HRV = heart rate variability.



## A.4 Clinical Outcomes

*The follow section divides the relevant figures and tables into those describing the relationship between autonomic dysfunction and clinical outcomes.*

## A.4.1 Outcomes in Twins

Clinical Outcomes by HRV Emory Twins Study					
	Acceleration Capacity	Dyx	High Frequency HRV	Low Frequency HRV	Very Low Frequency HRV
Cardiovascular Death					
Model 1	1.21 (0.87, 1.68)	0.7 (0.58, 0.84)	0.81 (0.58, 1.12)	0.72 (0.52, 1.01)	0.66 (0.44, 1)
Model 2	1.16 (0.81, 1.65)	0.71 (0.58, 0.86)	0.78 (0.55, 1.12)	0.8 (0.55, 1.16)	0.71 (0.44, 1.15)
Model 3	1.15 (0.81, 1.64)	0.71 (0.58, 0.88)	0.79 (0.56, 1.13)	0.83 (0.57, 1.23)	0.73 (0.45, 1.18)
Model 4	1.18 (0.8, 1.73)	0.74 (0.6, 0.92)	0.78 (0.55, 1.1)	0.83 (0.54, 1.27)	0.75 (0.44, 1.28)
Model 5	1.17 (0.79, 1.74)	0.74 (0.59, 0.91)	0.78 (0.54, 1.12)	0.82 (0.53, 1.27)	0.76 (0.44, 1.29)
All Cause Mortality					
Model 1	1.74 (1.04, 2.89)	0.56 (0.43, 0.73)	0.72 (0.45, 1.14)	0.46 (0.3, 0.7)	0.42 (0.24, 0.75)
Model 2	1.8 (1, 3.24)	0.52 (0.38, 0.7)	0.61 (0.36, 1.03)	0.45 (0.27, 0.73)	0.4 (0.21, 0.78)
Model 3	1.87 (1.05, 3.33)	0.47 (0.33, 0.66)	0.6 (0.37, 1)	0.46 (0.28, 0.76)	0.41 (0.21, 0.82)
Model 4	1.79 (1, 3.2)	0.49 (0.34, 0.69)	0.63 (0.38, 1.03)	0.47 (0.28, 0.82)	0.44 (0.21, 0.89)
Model 5	1.65 (0.92, 2.98)	0.49 (0.34, 0.7)	0.68 (0.41, 1.13)	0.49 (0.28, 0.86)	0.48 (0.23, 0.99)

<sup>1</sup>Model 1 = HRV<sup>2</sup>Model 2 = Model 1 + Myocardial Perfusion Imaging<sup>3</sup>Model 3 = Model 2 + Age + BMI + Race<sup>4</sup>Model 4 = Model 3 + Cardiovascular Disease + Hypertension + Diabetes + Smoking<sup>5</sup>Model 5 = Model 4 + Depression + PTSD

Every unit increased in HRV had the associated hazard ratio (95% CI) for both overall and cardiovascular mortality. HRV was selected at 7 AM. HRV = heart rate variability.

### A.4.2 Circadian Outcomes in Twins

Clinical Outcomes by Circadian Autonomic Variability  
Emory Twins Study

	MESOR	Amplitude	Phi
All Cause Mortality			
High Frequency HRV	0.55 (0.26, 1.19)	0.61 (0.21, 1.79)	1.21 (0.9, 1.63)
Low Frequency HRV	0.28 (0.13, 0.61)	0.3 (0.08, 1.14)	1.14 (0.8, 1.61)
Very Low Frequency HRV	0.19 (0.06, 0.61)	0.03 (0, 0.83)	1.73 (0.97, 3.07)
Acceleration Capacity	2.06 (0.91, 4.68)	0.4 (0.08, 1.86)	1.05 (0.74, 1.5)
NA	0.74 (0.49, 1.13)	0.22 (0.06, 0.88)	1.01 (0.82, 1.25)
Dyx	0.42 (0.28, 0.62)	0.5 (0.3, 0.83)	0.93 (0.67, 1.28)
Cardiovascular Death			
High Frequency HRV	0.78 (0.47, 1.29)	0.71 (0.19, 2.64)	1.1 (0.89, 1.36)
Low Frequency HRV	0.53 (0.29, 0.99)	0.53 (0.16, 1.71)	1.07 (0.83, 1.38)
Very Low Frequency HRV	0.6 (0.24, 1.49)	0.08 (0, 1.22)	1.12 (0.78, 1.59)
Acceleration Capacity	1.61 (0.85, 3.05)	0.33 (0.07, 1.59)	1.11 (0.88, 1.39)
NA	0.78 (0.56, 1.08)	0.2 (0.07, 0.6)	0.94 (0.81, 1.09)
Dyx	0.5 (0.36, 0.68)	0.61 (0.42, 0.87)	0.88 (0.68, 1.13)

The HRV metrics are measured over 24 hours using cosinor statistics. Every unit increase in HRV had an associated hazard ratio (95% CI) for both overall and cardiovascular mortality. HRV = heart rate variability, LF = low frequency HRV, HF = high frequency HRV, VLF = very low frequency HRV, AC = acceleration capacity, MESOR = midline estimating statistic of rhythm, Amplitude = maximum distance from MESOR, Phi = shift of acrophase

## A.4.3 Outcomes in MIMS/MIPS

Outcomes Analysis for Mental Stress and HRV  
Traditional and Recurrent Event Models in MIMS/MIPS

	Death	Cardiovascular Death	Marginal	PWP Total Time	PWP Gap Time	Anderson Gill
Stress Low Frequency HRV (ln ms <sup>2</sup> )						
Model 1	0.74 (0.64, 0.87)	0.7 (0.58, 0.84)	0.81 (0.71, 0.93)	0.79 (0.68, 0.93)	0.8 (0.69, 0.94)	0.81 (0.71, 0.93)
Model 2	0.76 (0.64, 0.89)	0.7 (0.58, 0.84)	0.82 (0.71, 0.95)	0.8 (0.68, 0.95)	0.81 (0.7, 0.95)	0.82 (0.71, 0.95)
Model 3	0.73 (0.61, 0.86)	0.63 (0.51, 0.78)	0.81 (0.7, 0.94)	0.79 (0.66, 0.94)	0.8 (0.68, 0.95)	0.81 (0.7, 0.94)
Model 4	0.74 (0.61, 0.89)	0.64 (0.5, 0.81)	0.84 (0.72, 0.98)	0.79 (0.66, 0.95)	0.8 (0.68, 0.95)	0.84 (0.72, 0.98)
Model 5	0.73 (0.6, 0.89)	0.63 (0.5, 0.81)	0.8 (0.68, 0.94)	0.81 (0.67, 0.98)	0.82 (0.69, 0.97)	0.8 (0.68, 0.94)
Model 6	0.74 (0.6, 0.92)	0.64 (0.5, 0.83)	0.8 (0.68, 0.95)	0.82 (0.67, 1)	0.82 (0.69, 0.99)	0.8 (0.68, 0.95)
Stress High Frequency HRV (ln ms <sup>2</sup> )						
Model 1	0.75 (0.61, 0.91)	0.66 (0.52, 0.83)	0.85 (0.74, 0.99)	0.78 (0.66, 0.92)	0.82 (0.71, 0.94)	0.85 (0.74, 0.99)
Model 2	0.76 (0.62, 0.94)	0.66 (0.52, 0.84)	0.87 (0.75, 1.02)	0.79 (0.67, 0.94)	0.83 (0.72, 0.96)	0.87 (0.75, 1.02)
Model 3	0.74 (0.61, 0.92)	0.63 (0.49, 0.81)	0.85 (0.73, 1)	0.8 (0.67, 0.95)	0.83 (0.71, 0.97)	0.85 (0.73, 1)
Model 4	0.78 (0.62, 0.97)	0.65 (0.49, 0.85)	0.89 (0.75, 1.05)	0.8 (0.67, 0.96)	0.84 (0.72, 0.98)	0.89 (0.75, 1.05)
Model 5	0.78 (0.62, 0.97)	0.64 (0.48, 0.86)	0.86 (0.72, 1.02)	0.82 (0.68, 0.98)	0.85 (0.72, 0.99)	0.86 (0.72, 1.02)
Model 6	0.82 (0.64, 1.04)	0.66 (0.49, 0.89)	0.86 (0.71, 1.04)	0.84 (0.7, 1.01)	0.87 (0.74, 1.02)	0.86 (0.71, 1.04)

<sup>1</sup>Model 1 = MSIMI ~ HRV

<sup>2</sup>Model 2 = Model 1 + MSIMI

<sup>3</sup>Model 3 = Model 2 + Age + BMI + Sex + Race

<sup>4</sup>Model 4 = Model 3 + Smoking + Diabetes + Hypertension + Hyperlipidemia


<sup>5</sup>Model 5 = Model 4 + Known Coronary/Peripheral Artery Disease

<sup>6</sup>Model 6 = Model 5 + Depression + Post-Traumatic Stress Disorder

This summarises the Cox proportional hazard models for both censoring events and for recurrent event analyses. Estimates = HR (95% CI). Bolded terms signify p-value < 0.05. PWP = Prentice, Williams, and Peterson models, MSIMI = Mental Stress-Induced Myocardial Ischemia, LF = Low Frequency, HF = High Frequency, HRV = Heart Rate Variability


## **B   Supplementary Files**

### B.0.1 Poincaré Plot of HRV



The two Poincaré plots represent ECG data at 7 AM for a twin pair that are discordant for stress test results. Both axes are RR interval lengths in milliseconds. The x-axis coordinate represents the RR interval for an initial beat, while the y-axis coordinate represents the RR interval for the following beat, such that the  $(x, y)$  coordinate represents  $(RR_n, RR_{n+1})$ . Each subsequent coordinate is plotted in this way. The red points are beats that were slower than the previous beat, while the blue points were faster than the previous beat. The shape of the resulting plot is abstracted into a single descriptive index called Dyx. The first twin (left) had no myocardial perfusion deficits on stress testing with a  $Dyx = 3.7$ . The second twin (right) had an abnormal stress test with a  $Dyx = 1.7$ . This is referenced with permission (26).

### B.0.2 Cosinor Metrics



This is an example of a cosinor of LF HRV over the course of 24 hours, which is represented as a simple harmonic regression with specific attributes. These characteristics describe the characteristics of the diurnal variations. HRV = heart rate variability, M = MESOR, A1 = amplitude, P1 = phi (acrophase).